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1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of neurodegenerative dementia 
and contributes to 60–70% of all the dementia cases. By 2015, the global occurrence 
of AD was 27 million people, and the number is expected to double by 2050 (GBD 
2015 Disease, Incidence, Prevalence Collaborators, 2016). Higher prevalence and in-
cidence rates are reported in the age group over 60 years from North America and 
Western Europe followed by those from Latin America and China and its western-
Pacific neighbors (Reitz & Mayeux, 2014). Age can be considered as a principal risk 
factor for AD. The incidence of the disease doubles every 5 years after 65 years of 
age, with the diagnosis of 1275 new cases per year per 100,000 persons older than 
65 years of age (Querfurth & LaFerla, 2010). However, genetic subtypes of AD (~5% 
of the total AD patients) show earlier clinical manifestation of the pathology, for exam-
ple, from around the age of 45 (Mendez, 2017). 
1.2 Clinical presentation  
The clinical presentation of AD comprises symptoms related to cognitive decline par-
ticularly those related to the memory domain. Severity of the symptoms gradually in-
creases with the disease progression, starting with mild cognitive decline (short-term 
memory deficits) in pre-dementia phases. Mild cognitive decline then develops into the 
early phase of dementia with difficulties in perception, language (vocabulary and 
speech fluency), and motor coordination. These clinical symptoms result from the de-
terioration of selective cognitive domains, particularly those related to memory. 
Memory decline initially manifests as a loss of episodic memory, which is considered 
a subcategory of declarative memory. The dysfunction in episodic memory impedes 
recollection of recent events including autobiographical activities. Elucidating the un-
derlying molecular determinants that trigger the disruption of recent episodic memory, 
and eventually the decline in the other cognitive domains, is among the most crucial 
unanswered questions in the AD field. Moderate and final stage AD cases exhibit an 




exhaustion. Overall, the decline in cognition makes the patient vulnerable to second-
ary illnesses such as ulceration and infections (Förstl & Kurz, 1999; Lopez, 2008). 
1.2.1 Senile plaques and neurofibrillary tangles 
Alzheimer’s disease is pathologically characterized by the occurrence of senile amy-
loid-β (Aβ) plaques and presence of intraneuronal neurofibrillary tangles (NFTs) of 
abnormally hyperphosphorylated Tau protein. Presence of plaques and tangles was 
first reported by Alois Alzheimer in 1907 (Alzheimer, 1907) and their biochemical na-
ture was first characterized in the 1980s. Although both Aβ plaques and Tau tangles 
are considered to be the specific hallmarks for Alzheimer’s disease, but the establish-
ment of AD pathology is complicated and includes many underlying alterations, mostly 
inflammatory response and oxidative stress resulting in defects in energy metabolism 
and synaptic dysfunction (Markesbery, 1997; Rozemuller, Eikelenboom, & Stam, 
1986; Simard et al., 2006; Wyss-Coray, 2006). 
1.2.1.1 Amyloid precursor protein and biosynthesis of amyloid-β 
The senile plaques prevalent in brain tissues of AD patients predominantly are con-
centrations of amyloid β peptides with a length of 42 amino acid residues (Aβ42). 
Whereas multiple variants (ranging from 36 to 43 amino acids in length) of Aβ itself 
are produced as cleavage products of the amyloid precursor protein (APP), monomers 
of Aβ40 are much more abundant physiologically than those of aggregation-prone and 
toxic Aβ42 species. 
The amyloid precursor protein is a single-pass transmembrane protein with a large 
extracellular domain. Alternate splicing of APP generates eight splice variants, of 
which three are most abundant: a 695 amino acid variant, which is expressed predom-
inantly in the CNS, a further two variants with 751 and 770 amino acids are more 
ubiquitously expressed (Bayer et al., 1999; O’Brien & Wong, 2011). Various Aβ spe-
cies are produced because of endoproteolytic cleavages of the parental APP. Three 
different types of enzyme complexes are involved in the endoproteolytic cleavages, 
namely α-, β- and γ-secretases. Three enzymes with α-secretase activity have been 
identified. These α-secretases belong to ADAM (a disintegrin- and metalloproteinase-
family enzyme) family of enzymes: ADAM9, ADAM10, and ADAM17 (Melo, Morgan, 
Monahan-Earley, Dvorak, & Weller, 2014). The β-secretase is a membrane integral β-




(Vassar et al., 1999). The γ-secretase has been identified as a complex consisting of 
presenilin 1 or 2, (PS1 and PS2), nicastrin, anterior pharynx defective and presenilin 
enhancer 2 (De Strooper, Iwatsubo, & Wolfe, 2012). APP proteolysis can be classified 
into two categories, i.e. non-amyloidogenic and amyloidogenic pathways. The non-
amyloidogenic pathway includes a cleavage of APP by α-secretase at the 83rd aa-
residue position from the C-terminus, resulting in a larger N-terminus ectodomain 
(sAPPα) released in the extracellular matrix. The C83 fragment remains in the mem-
brane and is subsequently cleaved by γ-secretase resulting in a p3 fragment which is 
released in the intracellular lumen. Importantly, the α-cleavage occurs in the Aβ region 
of APP, thereby eliminating the chances of Aβ formation. In comparison, in amyloido-
genic pathway APP undergoes a BACE1-mediated β-cleavage, at the 99th aa-residue 
position from C-terminus, resulting in sAPPβ released into the extracellular space, 
leaving a membranous 99-amino-acid C-terminus stub, known as C99. The C99 frag-
ment undergoes another cleavage event carried out by γ-secretase somewhere be-
tween the 38th and 43rd amino acid residues, liberating Aβ-peptide variants of different 
lengths (LaFerla, Green, & Oddo, 2007). 
 
Figure 1: Amyloidogenic and non-amyloidogenic processing of the amyloid precur-
sor protein. Non-amyloidogenic cleavage is conducted by ADAM family proteinases and 
results in shed-APP and C83 fragment, which is cleaved further by γ-secretase to give rise 
to an intracellular P3 fragment. Amyloidogenic cleavage, on the other hand, is initiated by 
BACE1 at the 83rd aa-residue from the C-terminal domain resulting in the C83 fragment, 
which after the second cleavage by γ-secretase results in Aβ peptide and an amyloid intra-




1.2.1.2 Tau tangles and their biosynthesis 
Microtubule-associated protein Tau is an abundantly occurring soluble protein, asso-
ciated with the cytoskeleton. Their abnormal hyperphosphorylation results in the 
switching of its soluble nature to a more hydrophobic one. These hydrophobic hyper-
phosphorylated Tau molecules are no longer attached to the microtubules and this 
results in self-association in the form of paired helical filaments (PHFs), which tend to 
further aggregate ultimately forming the inclusion bodies of Tau. The Tau tangles are 
not only characteristic of AD but are also present in many other neurodegenerative 
disorders, categorized as tauopathies. Like Aβ oligomers, the intermediate forms of 
Tau oligomers are considered cytotoxic and potentially causative in memory loss. In-
soluble helical filaments are believed to sequester the toxic Tau oligomers and prove 
to be inert to the neuron. Six isoforms of Tau are expressed in the adult human brain, 
and this isoform variation is a consequence of alternative splicing of exon 2 (E2), 3 
(E3) and 10 (E10). Exon 2 (E2) expresses N-terminal insert-N1, and E3 expresses N-
terminal insert-N2. Three N-terminal variations are possible, due to the presence or 
absence of either insert. Tau isoforms are categorized depending on the presence of 
three or four carboxy-terminal repeat domains (3R or 4R, respectively); the second 
repeat is encoded by E10 and is not included in 3R Tau (Querfurth & LaFerla, 2010).  
A battery of kinases and phosphatase is in action for the regulation of these site-spe-
cific phosphorylations in Tau protein molecules. Most of the kinases including PKA, 
CaMKII, PKC, and MAPKs (p38, ERK, SAPK and JNK) are transiently activated by 
exogenous and endogenous stimuli that result in the phosphorylation of Tau in healthy 
neurons. However, several Ser-Pro and Thr/-Pro sites are constitutively phosphory-
lated regulated by house-keeping kinase-protein kinases (Iqbal, Liu, Gong, & 
Grundke-Iqbal, 2010; Sengupta, Grundke-Iqbal, & Iqbal, 2006; Wang et al., 2012; 
Wang & Mandelkow, 2016). Mutations in the Tau gene (chromosome 17) are not re-
ported to have any association with the severity of neuronal loss in Alzheimer’s dis-
ease (Goedert & Jakes, 2005; Gómez-Isla et al., 1997). Nevertheless, increased p-
Tau and Tau levels in the cerebrospinal fluid (CSF) correlate with cognitive decline 





Figure 2: Structure of Tau protein: Tau protein can be subdivided into two major do-
mains. The assembly domain in the C-terminal region comprising the amino acid repeats 
(is responsible for binding to microtubules (MTs) and for Tau aggregation). The N-terminal 
domain is a projection domain and projects away from the MTs. The middle region of Tau 
(aa-residues 151–243) contains multiple Thr-Pro or Ser-Pro motifs that are hyperphosphor-
ylation targets of proline-directed kinases in tauopathies. Adapted from Wang and Mandel-
kow, 2016 
1.3 Genetic and non-genetic risk factors of Alzheimer’s disease 
Alzheimer’s disease-associated risk factors can be classified into two categories. The 
non-genetic risk factors (the factors having no established gene linkages to the AD) 
and genetic risk factors (including the genes, that have been proved to be associated 
with various aspects of Alzheimer’s disease). 
1.3.1 Non-genetic risk factors 
Non-genetic risk factors include, most conspicuously, cerebrovascular diseases, hy-
pertension (associated disintegration of blood-brain barrier), type 2 diabetes, plasma 
lipid levels, general health condition and traumatic injury to the head (Reitz & Mayeux, 
2014).  
1.3.2 Genetic risk factors 
Several genetic risk factors have been identified that are associated with different as-
pects of Alzheimer’s disease, mainly APP, Tau and cholesterol metabolism, immune 
response, endocytosis, and axon cytoskeleton. Highly linked genes include ADAM10, 
TREM2, PLD3, DSG2, CD2AP, and APOE (Karch & Goate, 2015). Among these AD-
associated genes, APOE polymorphism has been one of the most frequently studied 
risk factors. 
1.3.3 APOE polymorphism 
Apolipoprotein E (APOE) polymorphism is a well-established risk factor for Alzheimer’s 
disease. APOE is polymorphic with three major alleles in human population ε2, ε3, 




AD patients are carriers of the ε4-allele. Presence of at least one ε4 is associated with 
a reduction in the age of onset. APOE-ε4 allele homozygous carriers are reported to 
develop AD at least ten years earlier than the non-carriers. Nonetheless, early onset 
Alzheimer’s disease can develop in the absence of APOE-ε4. In contrast, some pro-
tection is provided by the presence of the rarer APOE-ε2 (Liu, et al., 2013; Strittmatter 
& Roses, 1995).  
1.4 Diagnosis 
The progression of Alzheimer’s disease is characterized using three major clinical 
methods, i.e., neuropsychological assessments, neuroimaging, and biomarkers.  
1.4.1 Neuropsychological assessments 
Neuropsychological assessments comprising a battery of tests, based on language 
skills, motor coordination, memory (learning and executive), intelligence and visual-
reception. These neuropsychological tests provide a rough estimation of disease se-
verity. Different testing strategies have been formulated, to estimate varying neuro-
psychological deficits e.g. General Practitioner Assessment of Cognition, Mental At-
tributes Profiling System, Mental Status Examination (MSE), Montreal Cognitive As-
sessment, NIH Stroke Scale, Abbreviated Mental Test Score, Mini-Mental State Ex-
amination (MMSE) and the Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD)-neuropsychological assessment (Morris et al., 1989; Peterson and Lantz, 
2001). CERAD-neuropsychological assessment consists of a battery of tests including 
verbal fluency, a modified Boston naming test, mini-mental state, language and con-
structional praxis (Morris et al., 1989). However, the most commonly used method for 
the neuropsychological assessment of AD is MMSE, for multiple reasons; foremost 
the simplicity of its application (Arevalo-Rodriguez et al., 2015; Pozueta et al., 2011; 
Tombaugh, McDowell, Kristjansson, & Hubley, 1996). The MMSE is a 30-score testing 
system that engages different cognitive and motor domains. A score of 24 or more 
points out of 30 is considered normal. A score below 24 can indicate a mild (19–23 
points), moderate (10–18 points) or severe (≤9 points) cognitive impairment (Mungas, 
1991; Roselli et al., 2009). Certain statistical corrections are applied to surpass differ-
ences in the educational background of the patients (Crum, Anthony, Bassett, & Fol-




that a repeated temporal testing profile can reflect the progression rate of the disease 
(Musicco et al., 2009). 
1.4.2 Neuroimaging 
An endorsement to the neuropsychological examination is made by utilizing neuroim-
aging approaches. A variety of neuroimaging methods have been designed to provide 
specific insights into different structural or functional aspects of the brain. The table 
below provides a summary of these imaging techniques and their respective applica-
tions. 




Acquired information Alterations observed in AD 
sMRI Provides information regarding the general 
structure and distribution of white matter, 
gray matter and CSF in the brain  
Medial temporal lobe atrophies, hippo-
campal atrophy. A compensatory in-
crease in the prefrontal cortex has also 
been reported by some authors (Lehé-
ricy et al., 1994; Scahill, Schott, Ste-
vens, Rossor, & Fox, 2002). 
fMRI  Provides insight into the synaptic activity 
dependent on the alterations of blood flow 
and oxy/deoxyhemoglobin ratios (Kwong 
et al., 1992; Ogawa, Lee, Nayak, & Glynn, 
1990) 
Decreased hippocampal activity is ob-
served in AD patients while performing 
episodic memory tasks (Hämäläinen et 
al., 2007; Rombouts et al., 2000) 
CT Gross brain anatomical study Used as a confirmation technique for 
MRI (Ferreira & Busatto, 2011) 
SPECT Regional brain perfusion (Ferreira & Bus-
atto, 2011) 
 
FDG-PET This is a version of positron emission to-
mography that utilizes fluorescence-
tagged glucose (F-fluorodeoxyglucose) 
and assesses the synaptic activity directly 
by measuring the glucose consumption in 
different brain regions (Johnson, Fox, 
Sperling, & Klunk, 2012). 
Hypometabolism in the limbic and asso-
ciated region (De Santi et al., 2001) 
Amyloid-
PET 
Deposition of amyloid fibrils is assessed in 
the brain using a radioactive compound 
that intercalates in amyloid fibrils 
(Ikonomovic et al., 2008) 
Utilized in both diagnosis and research 
settings, various groups have reported 
96% of AD patients as positive for the 
amyloids (Johnson et al., 2007; Perani, 
2014) 
sMRI = structural magnetic resonance imaging; fMRI = function magnetic resonance imag-
ing; CT = computerized tomography; PET = positron emission tomography, FDG-PET = 
18F-fluorodeoxyglucose-PET; SPECT = single photon emission tomography. 
1.4.3 Biomarkers for Alzheimer’s disease 
Alterations occurring in the brain due to neurodegeneration cast a disease-specific 




biochemical alterations can be utilized to depict and confirm the disease subtypes and 
stages. Biomarkers have been crucial in the differential diagnosis of neurodegenera-
tive diseases. To characterize a certain disease, it is common to rely on a set of bi-
omarkers. In the case of differential diagnosis of the AD, CSF biomarkers are consid-
ered the most reliable. Commonly measured biomarkers include Aβ40, Aβ42, Tau and 
p-Tau as their levels correspond to the amyloidosis and Tau pathologies respectively 
(Schaffer et al., 2015). The decrease in the Aβ42 marks an increase in amyloid plaque 
burden in the cerebral tissues. Conversely, Aβ42 levels alone cannot be relied for the 
differential diagnosis, as decrease in the Aβ42 is also observed in the subjects with 
mild cognitive impairment and even in the non-demented controls (Llorens, Schmitz, 
Ferrer, & Zerr, 2016). Increase in the CSF levels of Tau indicates an increase in the 
Tau protein and a higher degree of tangle formation in the brain (Humpel, 2011). Some 
studies also consider other subsidiary CSF biomarkers, including YKL-40, carnosi-
nase I, chromogranin A, and NrCAM (neuronal cell adhesion molecule) to increase the 
assay potential of Aβ and Tau levels (Schaffer et al., 2015).  
1.5 Neuropathological profiling of Alzheimer’s disease 
Current neuropathological assessment and staging for the AD are exercised according 
to the guidelines updated by the National Institute of Aging – NIA (Montine et al., 2012). 
NIA guidelines further take into account Aβ plaque scoring (Thal, Rüb, Orantes, & 
Braak, 2002), NFT staging (Braak & Braak, 1991) and CERAD scoring (Neuropatho-
logical staging of Alzheimer-related changes) (Mirra et al., 1991). Thus, the neuropa-
thological findings are ranked along three parameters (Amyloid, Braak, CERAD) to 
obtain an ABC score (Montine et al., 2012). The table below summarizes the A, B, and 
C scoring patterns used in NIA-AD staging. 
Table 2: A, B and C scoring used in the staging of Alzheimer’s disease according to 
National Institute of Aging guidelines. 
‘A’ Aβ plaque score ‘B’ NFT stage 
‘C’ Neuritic plaque score (modified 
from CERAD) 
A0: no Aβ  B0: no NFTs C0: no neuritic plaques 
A1: Thal phase 1 or 2 B1: Braak stage I or II C1: CERAD score: sparse 
A2: Thal phase 3 B2: Braak stage III or IV C2: CERAD score: moderate 
A3: Thal phase 4 or 5 B3: Braak stage V or VI C3: CERAD score: frequent 
The Thal Aβ plaque phases are defined by the presence of the senile plaques in dif-




Braak stages describe the spread of NFT lesions in diverse brain areas. Lesion profiles 
are described in Table 3. The CERAD stages are defined based on the frequency of 
plaques in the middle frontal cortex region of the brain. The stages range from no 
plaques to sparse, moderate and finally to frequent plaques (Mirra et al., 1991). 
Table 3: Lesion profiles of neurofibrillary tangles in diverse brain regions  
Braak 
stages 
Centers of NFT lesions 
I Transentorhinal region 
II Entorhinal region 
III Neocortex of the fusiform and lingual gyri 
IV Wider neocortical association areas 
V Frontal, superolateral, and occipital directions, reaching the peristriate region 
VI 
Secondary and primary neocortical areas and, in the occipital lobe, extends into the 
striate area 
1.6 Subtypes classification of Alzheimer’s disease 
Subtype classification of the AD can be based on two major factors, namely genetic 
background and the age of onset. Cases of genetic or early-onset familial AD (eFAD) 
account for only 1% of the total Alzheimer’s cases, where AD presentation is associ-
ated with the autosomal dominant mutations in three genes PSEN1, PSEN2, and APP. 
AD cases without any characterized associated genetic mutations are categorized as 
sporadic AD (Mendez, 2017).  
Both familial and sporadic cases prevail in two classes, based on their onset age. 
Sporadic AD cases are predominantly late-onset type, and the familial cases belong 
mainly to the early onset AD. Although cut-offs for the age of onset are arbitrary, the 
risk of developing AD is quoted to increase with the age. Based on the onset of dis-
ease, AD is subdivided into early-onset AD (EOAD), cases developing AD earlier than 
65 years of age (45-50 years of age) and late-onset Alzheimer’s disease (LOAD), i.e. 






Figure 3: Epidemiology of Alzheimer’s disease subtypes. Late-onset Alzheimer’s dis-
ease constitutes the largest percentage of the patients suffering from AD which is 95% of 
the total AD cases. About 4% of the AD cases are early-onset Alzheimer’s disease, and 
1% of all the AD cases are early-onset familial AD cases. 
1.6.1 Atypical pathological presentation in Alzheimer’s disease 
Alzheimer’s disease is a slowly progressive neurodegenerative disease. Disease 
course typically is associated with gradually developing symptoms related to the hip-
pocampal abnormalities – cognitive decline. However, some atypical AD cases pose 
variation in the pathological centers in the brain leading to a higher disease progres-
sion (Jack et al., 1998; Mueller et al., 2010). Giannakopoulos, Bouras, and Hof (1994) 
have reported an AD case with a higher extent of cortical degeneration compared to 
the hippocampal damage. Greater damage in occipital-parietal cortex relative to frontal 
and temporal cortices has been reported in a cohort of AD cases by Hof, Bouras, 
Constandinidis, and Morrison (1989). Likewise, two distinct groups of AD cases have 
been classified by Murray et al. (2011). The study discusses a group of Alzheimer’s 
disease with relative sparing of hippocampal regions (these cases with hippocampal 
sparing were observed to have a higher degree of Lewy body disease as well). The 
second group described in the study presents Alzheimer’s pathology centered in the 




1.7 Rapidly progressive Alzheimer’s disease  
Alzheimer’s disease is a slowly progressive neurodegenerative disease and typically 
spans a period of 8 years with gradually developing severity of symptoms, hence eas-
ily differentiable from the rapidly progressive dementia cases. The neuropsychological 
decline, when assessed by a Mini Mental State Examination, averages a drop of less 
than 6 MMSE units per year. Some atypical cases of AD, on the other hand, exhibit a 
neuropsychological profile that resembles the rapidly progressive dementias. In these 
cases, the average cognitive decline is more than 6 MMSE units per year. The preva-
lence of and reports on such cases are low. The post-diagnostic survival time in these 
cases is around 4 years in comparison to 8 years in typical spAD cases. Due to the 
atypical disease progression, such AD cases are often misdiagnosed as Creutzfeldt-
Jakob-disease in the dementia centers, and post-mortem pathological observations 
then later confirmed the Alzheimer’s pathology (Schmidt et al., 2011).  
1.7.1 History 
The literature is still sparse with its accounts of rpAD. The first case of rapidly progres-
sive AD (rpAD) mimicking CJD was reported in 1989 (Mann, Mohr, & Chase, 1989), 
followed by another report in 2004 with detection of 14-3-3 in CSF and subsequent 
classification of the patient as a CJD case, where postmortem pathological examina-
tion revealed the occurrence of AD pathology (Reinwald, Westner, & Niedermaier, 
2004). Protein 14-3-3 presence in CSF has been associated to CJD and is considered 
a very crucial differential biomarker for the detection of CJD (Aksamit, Preissner, & 
Homburger, 2001; Green et al., 2001; Zerr et al., 2000). A case of rapidly progressive 
AD was again reported to be positive for 14-3-3 by Jayaratnam and coworkers 
(Jayaratnam, Khoo, & Basic, 2008). 
1.7.2 Clinical features 
Detailed clinical features of rpAD have been studied by Schmidt et al. (2010). The 
study encompassed various aspects related to the disease, including the age of dis-
ease onset, gender, CSF biomarkers, clinical presentation and genotypes for APOe 
and PRNP. The disease duration from clinical examination was reported 26.4 months 
(median) and the age at death was reported to be 73 years (median). The gender ratio 




dementia were not reported, whereas the pathology was in accordance with Alz-
heimer’s pathology. Two cases were reported with a very low degree of Lewy body 
pathology. The most frequent signs included myoclonus (75%), gait disturbance 
(66%), a positive Babinski’s sign (66%), rigidity (50%), aphasia (66%), falls (50%) and 
hallucinations (44%). Especially aphasia, myoclonus, and rigidity were symptoms pre-
dominantly appearing in advanced disease stages, while depression, disturbed gait 
and impaired concentration occurred rather early in the disease course (Schmidt et 
al., 2010). Neuropsychological predictors have been revisited for rpAD cases, based 
on MMSE scoring by Tosto and coworkers. The study indicates that a decline in the 
executive/language tasks is a significant predictive criterion for the rpAD cases, in 
contrast to spAD (Tosto et al., 2015). 
1.7.3 Biomarkers and genetic linkages 
In rpAD cases, CSF Tau levels were slightly lower than that of the AD and for CSF-
Aβ42 levels, no difference was seen in comparison with the typical AD cases. Approx-
imately one third (31%) of the rpAD cases were positive for 14-3-3. For APOE geno-
types, no ε4/ε4 homozygous subjects were found for the study cohort, ε2/ε4 combina-
tion was prevalent in 6% of the subjects, 31% of the cohort was reported to be ε3/ε4 
heterozygous, 6% were heterozygous for ε2/ε3 and the ε3/ε3 genotype was seen in 
the majority (56%) of the test group. PRNP codon 129 genotype did not influence the 
disease onset or clinical course. However, a statistically significant association of hal-
lucinations with methionine homozygous individuals and that of epileptic seizures to 
the non-MM individuals was noticed in the cohort (Schmidt et al., 2010). Same clinical 
findings including CSF 14-3-3 positivity (42% in the studied cohort), higher prevalence 
of MM-PRNP genotype, and absence of APOE ε4/ε4 homozygosity, were augmented 
by a multicenter update including cohorts from France, Germany, Japan, and Spain 
later in 2012 (Schmidt et al., 2012). The similar CSF biomarker profiles were re-estab-
lished for rpAD alongside an increase in p-tau/tau for rpAD in another cohort more 
recently (Ba et al., 2017). Table 4 provides a summary of CSF biomarker profile for 
differential diagnosis of Alzheimer’s disease subtypes (rapidly progressive forms and 






Table 4: An outlook of CSF biomarkers in variants of AD and CJD as indicated by 
Schmidt et al., 2010, 2011, 2012. 
CSF Biomarkers rpAD spAD sCJD 
Tau ↑ ↑ × 
p-Tau/Tau ↑↑ ↑ × 
Aβ1-42 ↓ ↓ × 
Aβ1-40 — — × 
Tau/Aβ1-42 ↑ × × 
14-3-3 ↑ × ↑↑ 
Synuclein-Alpha — — ↑↑ 
IL-8 — — ↑ 
MCP-1 — ↑ ↑ 
A signature elevation in proinflammatory cytokines (IL-6, IL-13, TNF-α, and G-CSF) 
exclusively in the serum of rpAD patients has been reported, suggesting a difference 
in immune activation mechanism in rpAD pathology (Stoeck, Schmitz, Ebert, Schmidt, 
& Zerr, 2014). Table 5 summarizes the serum pro-inflammatory biomarkers in rpAD, 
spAD and sCJD. 
Table 5: Pro-inflammatory cytokines significantly elevated in the serum of rpAD 
cases compared with spAD and CJD, as indicated by Stoeck et al., 2014. 
Serum Cytokines rpAD spAD sCJD 
IL-13 ↑↑ — — 
TNF-α ↑↑ — — 
G-CSF ↑↑ — — 
IL-6 ↑ — — 
1.7.4 Biochemistry of rpAD 
The difference in the progression rate in rpAD cases compared to the spAD cases has 
also been associated with distinct physicochemical oligomeric species of Aβ charac-
terized in the brain by Cohen et al. (2015). The study provides evidence of the exist-
ence of Aβ42 species composed of about 100 monomers that are stable to chaotropic 
denaturation. However, the discrepancy in oligomerization between rpAD and spAD 
has not been discussed (Cohen et al., 2015). 
Significant proteomic alterations in amyloid plaques have been discussed in a recent 
study by Drummond et al. (2017). The difference in the plaque proteomic makeup 
represents the distinction of rpAD from spAD. However, no such protein candidates 
were found in either group to highlight supposedly different mechanisms involved in 




the plaques from rpAD cases, suggesting the higher degree of synaptic dysfunction in 
the AD cases with rapid progression (Drummond et al., 2017). 
1.8 Proteopathic oligomers and neurodegeneration 
Neurodegenerative diseases are characterized by the development of pathological 
hallmarks, consisting of fibrillar structures of seeding proteins. In AD pathology, these 
are Aβ plaques and Tau tangles, in prion diseases these plaques consist of PrPSc, 
whereas in Parkinson’s and Lewy body dementia these fibrillar plaques are made up 
of α-synuclein. The formation of these pathological hallmarks is a sequential multi-
phasic process, starting from the misfolding of physiological forms of respective pro-
teins. This misfolding ability is commonly associated with mutations/polymorphisms in 
the protein (gene) sequences, innate dysregulation of protein-cleaving machinery or 
both. Misfolding of these proteins is associated with acquiring a β sheets-rich confor-
mation, and these β sheets-rich molecules, in turn, develop the capability of converting 
other physiological molecules to β sheets-rich molecules. The misfolded molecules 
have the tendency to polymerize in a variety of oligomeric species, i.e. dimers, trimers, 
tetramers, and so on, ultimately forming relatively stable fibrillar structures. The inter-
mediate soluble oligomers are biologically active and are believed to be cytotoxic spe-
cies. According to this hypothesis, the fibrils (contrary to initial beliefs) are the inert 
end products of the polymerization chain (Meredith, 2005). There is increasing evi-
dence of the toxicity of various amyloid oligomers. 
Animal experiments have demonstrated the toxic effects of the Aβ oligomers (AβOs) 
in vivo, resulting in memory loss and loss of synaptic plasticity (Cleary et al., 2005) He 
et al., 2012). Inhibition of long-term potentiation (LTP) has also been noted in response 
to naturally occurring AβOs (Walsh et al., 2002). Synaptic calcium currents in the cel-
lular models have also been altered in cell models when treated with AβOs (Nimmrich 
et al., 2008). Furthermore, two major populations of AβOs (type 1 and type 2) have 
been identified that are capable of plaque formation and neurotoxicity, respectively. 
The relative amounts of these specific types are also found to be different in vivo along 
with their differential immunoreactivity (Liu et al., 2015). The Aβ-dimers derived from 
AD brains have also been able to cause synaptic toxicity in rat models (Shankar et al., 
2008). In AD patients, AβOs levels also correlate with the degree of synaptic loss (Le-




associated with the neurotoxicity (Goedert, Masuda-Suzukake, & Falcon, 2017; 
Usenovic et al., 2015). Toxicity caused by other proteopathic proteins has also been 
reported for other neurodegenerative diseases. Oligomerization prone α-synuclein 
species have been associated with synaptotoxicity (Kalia, Kalia, McLean, Lozano, & 
Lang, 2013; Pieri, Madiona, & Melki, 2016; Stöckl, Zijlstra, & Subramaniam, 2013) and 
dysregulation of the kinesin-microtubule system (Prots et al., 2013). Similarly, various 
species of prion oligomers have been identified, affecting the disease progression 
rates and the disease subtypes (Choi et al., 2009; Haldiman et al., 2013; Safar et al., 
2015; Kim et al., 2011).  
1.9 Alzheimer’s disease and Prion protein 
1.9.1 Prion protein -structure, functions, trafficking and pathological strains 
The cellular form of prion protein (also known as CD230) is a glycoprotein encoded by 
PRNP gene on the chromosome number 20 in humans (Basler et al., 1986; Oesch et 
al., 1985). The expression of the protein is ubiquitous in the body with higher expres-
sion in the nervous tissues, specifically the brain, immune cells, and lymphoid organs 
(Linden et al., 2008). In nervous tissue, the localization of the PrPC is observed at the 
pre-synaptic and post-synaptic membranes and is reported to be necessary for normal 
synaptic function (Collinge et al., 1994; Herms et al., 1999). 
1.9.1.1 Structure and biosynthesis 
The primary sequence of prion protein consists of 253 amino acid residues containing 
two signal peptides, at the COOH-terminal and the NH2-terminal. Post-translational 
modification results in the physiological form of prion protein with a length of 208 amino 
acid residues. A physiological form of prion protein, PrPC occurs primarily along with 
low amounts of truncated, transmembrane PrPCtm (with C-terminal facing towards ER 
lumen) and PrPNtm (with N-terminal facing the ER lumen) (Hegde et al., 1998; Hegde, 
Voigt, & Lingappa, 1998). A GPI-anchor is attached to PrPC during its life cycle in the 
cell (Taylor & Hooper, 2006). Newly synthesized PrPC enters the ER lumen with the 
assistance of an N-terminal signal peptide where core GPI-anchor is added after the 
removal of the C-terminal signal peptide followed by an assemblage of PrPC molecules 
in the lipid rafts. Association of PrPC to the raft is necessary for its proper folding and 




(Haraguchi et al., 1989), and formation of a disulfide bond between two cysteine resi-
dues at amino acid residues 179 and 214 in human PrPC (Turk et al., 1988) in ER and 
Golgi apparatus respectively (Campana, Sarnataro, & Zurzolo, 2005; Sarnataro, Cam-
pana, & Paladino, 2004). In addition, mature PrPC contains 5 octapeptide repeats with 
a PHGGGWGQ sequence near the NH2-terminal. 
 
Figure 4: Structure of mature physiological prion protein (PrPC). Disulfide linkage is 
presented between aa residues 179 and 214. Two glycan bodies are attached at aa resi-
dues 181 and 197. A GPI (glycophosphoinositol) anchor is added at the 230th aa residue. 
OR = octa-repeats region; HC = hydrophobic core; α = alpha helix domain; β = beta sheet 
domains. Adapted from Zahn et al., 2000 and Linden et al., 2008. 
In neurons, the cell surface retentivity is very short-lived, like other classical membrane 
receptors, i.e. a t1/2 of 3-5 min. The endocytosis is rather enigmatic. In different cells 
and different physiological conditions, internalization via both clathrin- and non-clath-
rin-coated vesicles has been reported (Sunyach, 2003).  
 
Figure 5: Biosynthesis and trafficking of the cellular prion protein. PrPC is synthesized 
in the ER (A) and is translocated via the Golgi apparatus (B) to the cell surface, residing at 




mediated either via clathrin-coated pits (E) or caveolae (yellow) (F), or PrPC is transported 
back to the cell surface being part of recycling endosomes (brown) (G). Adapted from: 
Lewis & Hooper, 2011. 
1.9.1.2 Signaling mediated by the PrPC 
The expression of the prion protein on the cell surface implies its avid function as a 
cell receptor. PrPC is discussed to be involved in many signaling pathways. A contro-
versial signaling pathway involves the caveolin-mediated signaling induced by PrPC. 
The cascade is hypothesized to work via N-CAM, which in turn activates the Fyn path-
way (He & Meiri, 2002). PrPC is also involved in modulating the cAMP/PKA pathway 
with significant biological consequences, with various possibilities of cAMP phosphor-
ylation being discussed, including heterotrimeric G proteins engaged by G protein-
coupled receptors (GPCR) (Cooper & Crossthwaite, 2006; He & Meiri, 2002; Kame-
netsky et al., 2006). Likewise, Erk activation, via the activation of Ras GTPases, is 
also achieved by the interaction with the PrPC (both forms, membrane-anchored and 
extracellular forms). Ras GTPases after their activation by binding of Grb2 adaptor 
protein to phosphorylated cytosolic domains of receptor tyrosine kinases, result in the 
changes of cellular Ca2+ levels (Spielhaupter & Schätzl, 2001; Stork & Schmitt, 2002). 
PrPC is also reported to promote the cellular influx of Ca2+ via a voltage-gated calcium 
channel (Fuhrmann et al., 2006; Herms et al., 2000). PrPC crosslinking promotes the 
Ca2+influx, which in turn acts as feedback for the lateral distribution of surface proteins 
including PrPC itself. Crosslinking of PrPC also recruits the non-receptor tyrosine ki-
nases including Fyn (discussed earlier) and lymphocyte-specific protein tyrosine ki-
nase to PrPC-containing membrane rafts (Stuermer et al. 2004). Protein kinase C is 
also reported to be activated by the PrPC, but the mechanism of activation is poorly 
understood (Dekker, Palmer, & Parker, 1995). A PrPC mediated neuroprotective role 
of PI3 kinase/Akt signaling is suggested to protect the neurons against oxidative stress 
(Vassallo et al., 2005; Weise et al., 2006). Interaction of PrPC with neural cell adhesion 
molecule (NrCAM) (Schmitt-Ulms et al., 2001) induces neurite formation. 
1.9.1.3 Prion diseases and conversion of PrPC into PrPSc  
The physiological conformation of cellular prion protein contains about 40% alpha-
helical structure and 3% β-sheets, and this proportion of secondary structures is com-
plementary for PrPC to perform cellular functions. In transmissible spongiform enceph-




conformation (43% β-sheets and 30% alpha helix) and the misfolded form of prion 
protein is referred to as the scrapie form (PrPSc). The PrPSc is extremely resistant to 
proteolysis and tends to have the ability to convert other PrPC molecules to PrPSc forms 
(Prusiner, Groth, Bolton, Kent, & Hood, 1984; Prusiner, Scott, DeArmond, & Cohen, 
1998). The process of PrPC to PrPSc conversion is also accompanied by oligomeriza-
tion of the PrPSc species, resulting in its cytotoxicity. These oligomers are finally con-
verted into the amyloid fibrils and plaques which are characteristics of prion dementias 
(Figure 6).  
 
Figure 6: Conformation changes in prion protein. Conversion of α-helix-rich PrPC (A) to 
β-sheets rich PrPSc (B), marks the beginning of pathological events in prion neurodegener-
ation. PrPSc molecules are then hypothesized to form planer trimers (C) and the trimers 
stack up over each other to form the fibrils (D). Modified from Stroylova et al., 2014. 
Multiple types of transmissible spongiform encephalopathies (TSEs) in humans and 
animals are associated with prion protein strains. The pathological hallmarks are spon-
giosis and formation of PrPSc plaques in the brain. Human prion diseases are detailed 





Table 6: Classification of human prion disease. Modified from Gambetti et al., 
2003.  
 
Animal prion diseases comprise a large group of diseases targeting various animal 
species, detailed in Table 7. 
Table 7: Animal prion diseases and proposed etiologies. Source: modified from Imran 
and Mahmood, 2011. 
Disease Host Proposed Etiology 
Scrapie Sheep, Goats Infection with prions of unknown origin 
Transmissible Mink Encephalopathy 
(TME) 
Mink 
Infection with prions of either sheep or 
cattle origin 
Chronic wasting disease (CWD) Cervids Infection with prions of unknown origin 
Bovine spongiform encephalopathy 
(BSE) 
Cattle Infection with prions of unknown origin 
Exotic ungulate spongiform encephalo-
pathy (EUE) 
Nyala, Kudu Infection with prions of BSE origin 
Feline spongiform encephalopathy 
(FSE) 
Cats Infection with prions of BSE origin 
TSEs in non-human primates Lemurs Infection with prions of BSE origin 
 
  





Mutations in PRNP gene 





 Mixed or undefined forms  
Sporadic CJD (sporadic) No association with the mutations in 
PRNP gene, but the phenotypes are 
affected by the PRNP codon 129 
polymorphism (MM, VV, MV), and 
type of PrPSc strain (1 or 2, defined 
by proteinase-K digestion) (Cali et 
al., 2009; Gambetti et al., 2003) 
 Typical (MM1 and MV1) 
 Early onset (VV1) 
 Long duration (MM2) 
 Kuru plaques (MV2) 
 Ataxic (VV2) 
 Sporadic Familial Insomnia (sFI)  
Acquired Kuru Exposure to human brain material 
 Iatrogenic CJD (iCJD) 
Exposure to PrPSc during transfu-
sion 
 Variant CJD (vCJD) 
Acquired from the bovine spongi-





1.9.2 Involvement of prion protein in Alzheimer’s disease 
1.9.2.1 Prion-like behavior of Aβ and tau 
Primary interest to study the prion protein in association with Alzheimer’s pathology 
arose due to the similarities between the mechanisms of misfolding, transformation 
and spread of prion protein, Aβ and Tau. Toxicity in Alzheimer’s disease is primarily 
due to the conversion of alpha-rich molecules of Aβ and Tau to the β-sheets-rich mol-
ecules, much like the prion conversion to PrP-scrapie forms (Frost & Diamond, 2010; 
Goedert, Clavaguera, & Tolnay, 2010; Jucker & Walker, 2011). Much like the PrPSc, 
the Aβ and Tau also exhibit the seeding activity, i.e. misfolded molecules can trans-
form other normal Aβ and Tau forms to the toxic forms, in turn starting a spread chain 
(Braak and Del Tredici 2011; Brettschneider et al. 2015; de Calignon et al. 2012; Harris 
et al. 2010). Transmissibility has also been observed for AD. Brain homogenates from 
AD patients, when inoculated into the hippocampus of mice, initiated an Aβ deposition 
in mice. The spread of the Aβ and Tau in the brain also resembles the spread of PrPSc 
(Kim & Holtzman, 2010; Novak, Prcina, & Kontsekova, 2011; Prusiner, 1984). 
1.9.2.2 PrPC inhibition of BACE1 
The N-terminal domain of membrane-anchored PrPC is reported to regulate the for-
mation of Aβ, by inhibiting BACE1 cleavage activity subjected on APP. BACE1 inhibi-
tion activity is associated with the localization of PrPC to the membrane rafts, as the 
activity is lost in the PrPC variants which are not associated with the rafts. Membrane 
raft-associated mutant forms of PrPC, formed in familial prion diseases, are reported 
to lose their BACE1 inhibition, suggesting that structural integrity and sequence con-
servation are also important factors required for BACE1 inhibition activity in PrPC (Par-
kin et al., 2007). Likewise, loss of BACE1 inhibition is also reported in the scrapie-
infected humanized mice, resulting in subsequent higher levels of Aβ40 and Aβ42 (Par-
ton, Joggerst and Simons, 1994; Sunyach, 2003; Linden et al., 2008).  
1.9.2.3 PrPC as a receptor for Aβ oligomers 
The cellular prion PrPC is a well-characterized receptor for of amyloid-β oligomers. 
Hippocampal CA1 long-term potentiation is suppressed under the effect of nanomolar 
concentrations of Aβ treatment. However, this LTP suppression is not observed in the 




APPswe/PSen1DeltaE9 transgenes in PrP-/- condition do develop the amyloid plaques 
but memory functions are conserved, suggesting the involvement of PrPC in amyloid 
toxicity (Parton et al., 1994). PrPC after the attachment of Aβ is believed to initiate the 
Fyn signaling cascade resulting in the phosphorylation of the NR2B subunit of N-me-
thyl-D-aspartic acid receptors resulting in a transient increase in surface NR2B and 
subsequent excitotoxicity and destabilization of dendritic spines. Activated Fyn also 
acts as a kinase for Tau phosphorylation (Roberson et al., 2011). 
1.9.2.4 PrPC alpha- cleavage shedding by ADAMs, controlling the fibrillation of Aβ 
The N-terminus of the PrPC is responsible for the attachment of Aβ to the prion protein 
(Fluharty et al., 2013). Physiologically, under the action of ADAM-10, PrPC undergoes 
alpha-cleavage between amino acids 111/112, resulting in the formation of N1 and C1 
fragments, both resultant fragments keep their neuroprotective roles in the AD and 
CJD, respectively (Altmeppen et al., 2012). A detachment of the N1 fragment from the 
PrPC eliminates the possibility of Aβ anchorage to the PrP molecules, hence no sub-
sequent Fyn signaling cascade operates in the cell. On the other hand, the release of 
N1 fragments in the outer cellular space, allows the sequestering of Aβ-oligomers, 
sequentially minimizing the chances of their attachment to cell surface PrPC. ADAM-
10 is also responsible for the shedding of PrPC from the cell surface which in turn 
behaves as a bait for the soluble Aβ-oligomers (Altmeppen et al., 2011, 2012; Rob-
erson et al., 2011). 
1.9.2.5 Codon 129 polymorphism and onset of AD 
A linkage between the polymorphism at codon 129 and early onset of the AD has been 
discovered in various studies. A higher risk of developing AD with early onset has been 
associated with codon 129 valine homozygosity in patients from Dutch and Polish co-
horts (Dermaut et al., 2003; Golanska et al., 2004), whereas a higher risk of developing 
early AD-associated to PRNP codon 129 methionine homozygosity is reported from a 
German cohort (Riemenschneider et al., 2004). However, no such associations could 
be seen from the patients from Spain, Italy or Japan. These linkage differences can 
be explained by a strong effect of ethnicity. In any case, there is a dose-dependent 
relation between memory decline in the AD and PRNP codon 129 valine (Casadei et 




1.10 Study objectives 
The progression rate in rpAD cases mimics the characteristics of prion diseases. Like-
wise, rapid progressive Alzheimer’s disease has also been attributed to distinct prion-
like oligomers of Aβ (Cohen, Appleby, and Safar, 2016). However, the mechanistic 
details of progression rate variations in rpAD have not been studied previously. 
The current study primarily focusses on defining differential signal transduction path-
ways, physiological regulation of prion protein in rpAD and oligomer metabolism. Ex-
periments in the current study, utilize cerebral cortex samples from patients with spAD, 
rpAD, age-matched controls and other rapid dementias as positive controls. Details of 
the cohort are discussed in the “Methods” section.  
Objectives of the study were 
1. to characterize pathological hallmarks of Alzheimer’s disease (Aβ plaques and 
tangles), 
 
2. to identify and characterize differential signal transduction mechanisms in-
volved in the progression rate variations, 
 
3. to study the differential metabolism of prion protein and subtype-specific inter-
acting partners in rpAD and spAD, 
 
4. to isolate and characterize the oligomers of prion protein and other proteopathic 
proteins and their influence on progression rate, and 
 
5. to study the mechanism of proteopathic oligomer toxicity in rpAD. 
  
Materials and methods 
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2 Materials and methods 
2.1 Materials 
2.1.1 Antibodies 
Antibodies used for immunofluorescence (IF), immunoprecipitation (IP), immunoblot-
ting (IB), and are listed in Tables 1 and 2. 
Table 8 : List of primary antibodies and their applications in the current study 





Company / Cat. No. 
SAF 70 (anti PrP antibody) Mouse IgG2b 1:1000/1:100 1:100 SPIbio / A03206 
Actin-beta Mouse IgM 1:10000 1:100 Sigma / A5441 
Zinc Alpha 2 Glycoprotein Mouse IgG1 1:1000/ 1:100 1:100 Abcam / ab117275 
Peroxiredoxin-1 Rabbit IgG  1:1000 - Abcam / ab15571 
GAPDH  Mouse IgM 1:10000 - Sigma / G8795 
AKT Rabbit IgG 1:1000 - CST / 9272 
Phospho-Akt (Ser473) Rabbit IgG 1:1000 - CST / 4060 
GSK3-B Rabbit IgG 1:1000 - CST / 12456 
Phospho-GSK-3β (Ser9) Rabbit IgG 1:1000 - CST / 5558 
ERK 1/2 MAPK Rabbit IgG 1:1000 - CST / 4695 
Phospho-ERK 1/2 MAPK Rabbit IgG 1:1000 - CST / 4370 
p38 MAPK Rabbit IgG 1:1000 - CST / 8690 
Phospho-p38 MAPK Rabbit IgG 1:1000 - CST / 4631 
Tau Rabbit IgG 1:1000 - Abcam / ab64193 
Tau phospho (S199) Rabbit IgG 1:5000 1:100 Abcam / ab4749 
Tau phospho (S199 + S202) Rabbit IgG - 1:100 GeneTex / GTX24864  
6E10 (anti amyloid beta an-
tibody) Mouse IgG 
1:1000 1:100 
Biolegend / 803001 
4G8 (anti amyloid beta anti-
body) Mouse IgG 
1:1000 1:100 
Biolegend / 800701 
G2L2 Rabbit IgG 1:1000 1:100 Abcam / ab170275 




Tubulin-alpha Mouse IgG 1:1000 1:100 
Santacruz biotech. / 
sc-58667 
 
Table 9: List of secondary antibodies and their applications in current study 
Secondary antibody Origin Dilution (IB) Dilution (IF) Company/ Cat. No. 
α-Mouse-HRP  Goat 1:10000 - JacksonIR Lab / 115-035-062 
α-Rabbit-HRP  Goat 1:10000 - JacksonIR Lab / 111-035-144 
α-Goat-HRP Goat - 1:200 JacksonIR Lab / 705-035-003 
α-Mouse-A488  Goat - 1:200 Thermo Fischer Sci. / A32723 
α-Rabbit-A488 Goat - 1:200 Thermo Fischer Sci. / A-11034 
α-Mouse-A546 Goat - 1:200 Thermo Fischer Sci. / A-11003 
α-Rabbit-A546 Goat - 1:200 Thermo Fischer Sci. / A-11010 




Chemicals used in the study were purchased from Sigma-Aldrich, Fluka (Deisenhofen, 
Germany), Merck (Haar, Germany), Roth (Karlsruhe, Germany), BioRad (München, 
Germany) and Amersham (Freiburg, Germany), or are otherwise mentioned in the 
text. 
2.1.3 Kits 
Kits used for the study included 
i) High throughput Co-IP kits (catch and release HT immunoprecipitation kit, 
Cat. No.17-501, Merck) 
ii) Pierce High pH Reversed-Phase Peptide Fractionation Kit, Thermo Fisher 
Scientific 
2.1.4 Laboratory equipment and other materials 
The table below lists the instruments and other materials used in the study. 
Table 10: Instruments and other materials used in the study 
Appliance Model / Description Company 
Tissue lyser LT 85600 Qiagen, Hilden, Germany 
Tabletop ultracentrifuge Optima™ TL 100 Beckman coulter, Krefeld, Germany 
Refrigerated centrifuge  5415 C Eppendorf, Hamburg, Germany 
Speedvac SPD111V Sigma-Aldrich, Savant 
Picofrit reversed phase-C18 
column  
0.075 mm ID × 200 
mm 
New Objective, Woburn, USA 
Hybrid quadrupole/orbitrap 
mass spectrometry system  
Q Exactive 




Eksigent nanoLC425 AB Sciex, Darmstadt, Germany 
Mass spectrometer TripleTOF 5600+ AB Sciex, Darmstadt, Germany 
Protean i12 IEF system 164-6000 Bio-Rad, Munich, Germany 
Floor ultracentrifuge Optima™ TL 60 Beckman coulter, Krefeld, Germany 
Swinging bucket rotor SW-55ti  Beckman coulter, Krefeld, Germany 
Thin wall Polyallomer tubes  13 x 51mm Beckman coulter, Krefeld, Germany 
ChemiDoc ™ XRS+ system 170-8265 Bio-Rad, Munich, Germany 
Mini-PROTEAN Tetra Cell 1658004EDU Bio-Rad, Munich, Germany 
PVDF membrane 
Amersham Hybond P 
0.2 
GE Healthcare Life Sciences  
Nitrocellulose membrane 
Amersham Protran 0.2 
NC 
GE Healthcare Life Sciences  
Semi-Dry transfer cell 
Transblot Turbo trans-
fer system 
Bio-Rad, Munich, Germany 
Power supply Power Pac 300 Bio-Rad, Munich, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Microscope Leica TCS SPE Leica, Wetzlar, Germany 
 




The following software were used in the study. 
Table 11: List of software used in study 
Software Use References 
LabImage 2.7.1 Densitometric analysis  Kapelan GmbH, Halle, Germany 
ImageJ 1.51j8 Co-localization analysis National institutes of Health, USA 




Thermo Fisher Scientific, Dreieich, Ger-
many 
Excalibur v2.4 software 
Instructing Mass spectrome-
ter  AB Sciex, Darmstadt, Germany 
Scaffold 4.8.4 MS/MS data analysis Proteome Software, Inc 
Perseus MS/MS data analysis MPI of Biochemistry, Martinsried, Germany 
Zeiss LSM 4.2.0.121 Immunofluorescence  MicroImaging GmbH, Göttingen, Germany 
R version 3.4.3 Statistical analysis  
Graphpad Prism 6 Statistical analysis GraphPad Software, Inc. California, USA 
 
2.1.6 Stock Solutions 
Lysis Buffer I: 2 M thiourea, 7 M urea, 4% CHAPS, 66 mM DTT and 0.5% ampholytes 
Tissue-Lysis Buffer II: 2% sarkosyl in PBS (without Ca2+ and Mg2+) 
Lysis Buffers for subcellular protein enrichment:  
NP-40 lysis buffer: 50 mM Tris HCl, pH 7.6, 0.01% NP-40, 150 mM NaCl, 2 mM 
EDTA and 0.1% SDS 
TNT lysis buffer: 50 mM Tris HCl, pH 7.4, 150 mM NaCl and 0.1% Triton X-100 
RIPA buffer: 50 mM Tris HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 
3% SDS and 1% deoxycholate 
Rt-QuIC reaction Buffer: 162 mM phosphate buffer (pH 6.9), 170 mM NaCl, 1 mM 
EDTA, 10 μM thioflavin-T, 0.1 mg/mL recPrP. 
Citrate buffer (pH 6.0): 10mM sodium citrate (pH 6.0) 
Laemmli Buffer (4x): 2.0 mL 1M Tris-HCl pH 6.8, 1.0 mL 0.5 M EDTA, 4.0 mL 100% 
glycerol, 0.4 mL 14.7 M β-mercaptoethanol, 0.8 g SDS, 8 mg bromophenol Blue. 
Tris-glycine electrophoresis buffer 10x (1L): 144 g Glycin, 30 g Tris, 10 g SDS, 
ddH2O  
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Resolving gel buffer: 1.5M Tris, 2% SDS (pH 8.8), ddH2O 
Transblot buffer 10x: 48 mM TRIS, 39 mM Glycin, 1 mM SDS  
TBS-T: TBS and 0.1% of Tween-20 
Blocking solution for immunoblotting: 5% Milk Powder in TBS-T 
Silver staining solutions 
Developing solution: 6% Na2CO3, 0.0185% formaldehyde, 16 μM Na2S2O3 in 
ddH2O 
Fixation solution: 50% methanol, 12% acetic acid in ddH2O 
Sensitizing solution: 0.8 mM Na2S2O3 in ddH2O 
Silver nitrate solution: AgNO3 0.2% and 0.026% formaldehyde in ddH2O 
Peptide digestion and extraction solutions 
Reducing buffer: DTT (10 mM in 100 mM NH4HCO3) 
Alkylation buffer: IAA (55 mM in 100 mM NH4HCO3) 
Porcine trypsin: 12.5 ng/µL in 50 mM NH4HCO3, 5 mM CaCl2  




An overview of methods used in the current study is given in Figure 7. The detailed 
methods are discussed below. 
 
Figure 7: Overview of methodology. The first phase of the study included the sample 
collection (brain autopsies), characterization for various pathological features and assess-
ment of biochemical regulations of kinases that are involved in the neurodegenerative dis-
eases. The prion protein metabolism was then studied. In the second phase, high-density, 
molecular species of PrP were isolated (using ultracentrifugation) and their biochemical 
composition was demonstrated using Co-IP. Additionally, other high-density molecules 
were studied using high-resolution mass spectrometry. Finally, the predicted interactors 
were studied for their physiological relevance in the disease cases. 
2.2.1 Sample collection and processing 
Frontal cortex samples from cohorts with spAD, rpAD, small vessel disease (SVD), 
rapidly progressive dementia with Lewy bodies (rDLB), dementia with Lewy bodies 
(DLB) and dementia with frontotemporal lobar degeneration, were provided by the 
Brain Bank of Institute of Neuropathology (HUB-ICO-IDIBELL Biobank) and Biobank 
of Hospital Clinic-IDIBAPS Spain. Frontal cortex samples from patients with sporadic 
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Creutzfeldt-Jakob disease (sCJD) subtypes were obtained from the Department of 
Neurology at the University Medical Center, Göttingen, Germany.  
A rapidly progressive Alzheimer’s disease cohort was composed of those patients who 
strictly fulfilled the following inclusion criteria: 
1. Initial classification as prion disease based on clinical parameters 
2. Neuropathological diagnosis of Alzheimer’s disease, due to an indication of AD 
pathological features, i.e., higher Braak and CERAD stages justifying AD diag-
nosis whereas assessment and diagnosis of the examining neuropathologist 
were accepted as an adequate neuropathological diagnosis in cases of una-
vailability of the data on CERAD / Braak staging). 
3. Exclusion of prion disease and other relevant, potential causes of rapid demen-
tia (i.e., extensive cortical Lewy body pathology (Braak stage ≥5.6), tumors, 
significant vascular disease, stroke, inflammation, etc.) based on the neuropa-
thological assessment. 
4. The absence of history suggestive of familial AD (autosomal dominant muta-
tions) 
In the case of agreement with all the above-stated inclusion criteria, patients of all 
ages were included in the study.  
One-centimeter thick sections were excised from one of the hemispheres. Dissected 
tissues were frozen rapidly and were later kept at -80ºC until further use for biochem-
ical investigations. The other hemisphere was fixed by immersion in 4% buffered for-
malin for three weeks. Neuropathological and morphological characterizations were 
made later. 
2.2.2 Pathological profiles  
Non-demented control samples included in the study belonged to Braak stage I – II. 
Brain cortex samples for Alzheimer’s subtypes were only included in the study if there 
were no co-pathologies. Braak stages (disease progression) in both spAD and rpAD 
were comparable and ranged from stage III to VI. The DLB cohort also included sam-
ples without any co-pathology (Braak stages I – III). Likewise, cortex samples from the 
sCJD (subtypes) cohort had pure prion pathologies. However, some brain samples 
included in rDLB, DFTL and SVD showed mixed pathologies. rDLB samples contained 
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co-existing AD pathology, tauopathy, progressive supranuclear palsy (PSP), and ar-
gyrophilic grain disease (AGD). Cerebral cortex samples from a DFTL cohort also 
showed features of motor neuron disease (MND) and TDP-43 pathology. All the SVD 
samples showed higher stages of AD pathology. Hippocampal sclerosis was also seen 
in one of the samples from the SVD cohort. Details of the studied cohorts are dis-
cussed in annexure data Table 14 to Table 16. 
There were no significant differences in the age distribution of pathological cohorts 
included in the study (Figure 8 and Figure 9A). When compared, post-mortem intervals 
among the studied cohorts were also not significantly different from each other. Figure 
9.B details the comparison of PMI in the studied cohorts. An overview of the sample 
cohorts is provided in Figure 8, and complete sample details are provided in the an-
nexure (Table 14-Table 16). 
2.2.3 Ethics statement 
Samples were handled following the local legislation (Ley de la Investigación Biomé-
dica 2013 and Real DecretoBiobancos, 2014). The Creutzfeldt-Jakob disease (sCJD) 
cohort was obtained after the approval of local ethics committees at the University 
Medical Center, Göttingen. 
 
Figure 8: Summary of frontal cortex cohorts used in current study. The details of the 
cohort are given in the annexure (Table 14-Table 16).  




Figure 9: Sample cohorts used in the study A) Comparison of ages of the diverse patho-
logical cohorts used in the study. B) Graph presents a comparison of post-mortem intervals 
to the time of autopsies. 
2.2.4 Protein extraction 
For immunoblotting and whole proteome mass spectrometric analysis, tissue slices 
were homogenized using a steel beads tissue disruptor (Qiagen), in ice-cold lysis 
buffer I to a final concentration of 10% w/v and were replenished with protease and 
phosphatase inhibitor cocktails (Roche). Homogenates were incubated at 4C over-
night. After ultracentrifugation at 40,000 xg at 4C for 30 min (Beckman Coulter ultra-
centrifuge), supernatants were taken and used further for downstream applications. 
Protein extractions performed otherwise are mentioned in the respective section, i.e. 
density gradient centrifugation, subcellular protein enrichments, and proteinase K di-
gestion. 
2.2.5 Protein concentration estimation 
The protein concentration of homogenates was determined using the Bradford assay 
(Bio-Rad). Dye reagent concentrate (Bio-rad) was diluted with ddH2O to prepare the 
working solution. The working solution of the dye was then filtered through Whatman 
filter paper before use. Bovine serum albumin (BSA) standards of serial concentrations 
were prepared in ddH2O with the concentrations ranging from 0-1 mg/mL. Protein 
samples with unknown concentration were diluted 1:10 or 1:20 before measurements. 
Protein standards or diluted samples were mixed with Bradford working solution fol-
lowing the kit instructions and were incubated for 10 min at room temperature (RT). 
Absorbance of the samples was measured at 595 nm. Absorbance measurements of 
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standards were used for calculating the standard curve, which in turn was used for 
estimating the unknown protein concentrations.  
2.2.6 SDS-PAGE and immunoblot analysis 
Bi-phasic gels, with a 4% stacking gel and a 12% resolving gel were used for separat-
ing proteins based on their molecular weights. Isolates containing equal protein 
amounts were mixed with the corresponding volume of 4x Laemmli buffer and were 
heated to 95C for 5 minutes in a thermomixer. Samples were loaded onto the gels 
along with suitable molecular weight protein marker (Bio-rad dual color precision plus 
protein standards). Electrophoresis was carried out at 100 V, until the loading dye 
reached the bottom of the resolving gel. Running buffer (1x) was prepared by diluting 
10x running buffer stock. To resolve the density variant fractions, ready to use 26 well 
criterion TGX, 4-12% gradient gels (Bio-Rad) were used instead. 
Relative protein expressions were assessed by immunoblotting. Resolved proteins 
were blotted onto PVDF or nitrocellulose membrane (0.2 µm pore size) from the gel, 
using semi-dry transfer at 14 V for 1 h. Transfer buffer (1x) was prepared with 20% 
methanol to use with PVDF and without methanol to use with nitrocellulose mem-
branes. After transfer, blots were blocked for 1 h at RT, using either 5% fat-free milk 
or 2.5% BSA depending on the antibody to be probed. 
After having been blocked, the blots were incubated with primary antibodies of differ-
ent specificities and dilutions (see Table 1) overnight at 4°C. Membranes were then 
washed with TBS-T (1x) and incubated with the respective horse radish peroxidase 
(HRP)-conjugated secondary antibody (see Table 2) for 1 h at RT. Immunoreactivity 
was detected after immersing the membranes in enhanced chemiluminescence (ECL) 
solution, followed by scanning using a Bio-Rad Chemidoc imaging system. 
2.2.7 Co-immunoprecipitation from frontal cortex lysates 
PrPC interacting proteins were isolated using Dynabeads protein G bead (Thermo 
Fischer scientific) bound to mouse monoclonal anti-prion (SPI Bio). To attach antibody 
molecules to protein G beads, the beads were prepared by washing with 1x PBS and 
twice with 0.3% CHAPS. The antibody was incubated to bind to protein G beads at 
manufacturer-recommended dilution for 20 min at 4°C on a tube rotator. Unbound an-
tibody was removed by separating beads on the magnet. Cortex protein isolates were 
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then introduced at a concentration of 1 µg/µL to antibody-bound beads overnight at 
4°C on a tube rotator. Unbound protein/complexes were taken out by pelleting protein 
G beads on the magnet. Beads were then washed four times with 0.3% CHAPS and 
transferred to a new tube to avoid non-specific elution of proteins bound to the tube 
wall. Proteins captured by antibody bound to Protein G beads were eluted either by 
denaturation of beads in 2x Laemmli buffer at 95°C for 5 min or by incubating beads 
with glycine buffer (50 mM, pH 2.5) for 2 min at RT in a tube rotator (eluates after 
glycine elution were neutralized with 1 M Tris, pH 9). The eluates were further used 
for immunoblotting and mass spectrometric identifications. 
2.2.8 Sub-cellular (extracellular, intracellular and membrane) proteins enrich-
ment 
Differentially enriched protein fractions, i.e. i) extracellular proteins, ii) intracellular pro-
teins, iii) membrane protein fractions, and iv) formic-acid-soluble protein aggregates, 
were isolated from human cortical tissues from patients with spAD, rpAD and non-
demented control cases to investigate the distribution of PrPC in the cerebral environ-
ment. These differential enrichments were prepared by following a previously de-
scribed protocol (Sherman & Lesné, 2011). Briefly, frozen cortex sections, weighing 
~150 mg, were taken in 500 µL of ice-cold NP-40 lysis buffer. Tissues were then ini-
tially homogenized mechanically using a 1 mL syringe without a needle (5 repeats), 
followed by passing the homogenates through the syringe after attachment of a 20-
gauge needle 5 times. Soluble components (mostly extracellular proteins, EC) were 
separated by centrifugation at 800 xg for 10 min at 4°C and transferred to a new tube. 
Following extraction of extracellular proteins, pellets were re-suspended in 500 µL of 
ice-cold TNT lysis buffer by passing the mixture through a 1 mL-pipette, 8 to10 times, 
to obtain a homogenous mixture. Soluble components mostly intracellular (IC) proteins 
were separated by centrifugation at 16,100 ×g for 90 min at 4°C and stored for later 
use. Following extraction of IC proteins, the resultant pellets were dissolved in 750 µL 
of RIPA buffer to extract membrane-bound proteins (MB). Pellets were homogenized 
thoroughly using a 1 mL-pipette (with 30 repeats) and thereafter vortexed for 20s. Ho-
mogenates resulting were then incubated at 4°C for 15 min on a rotating platform to 
enhance chemical lysis followed by centrifugation at 16,100 xg, 4°C for 90 min to sep-
arate the membrane-bound protein-enriched fraction (MB). Following removal of mem-
brane-associated proteins, resultant pellets were solubilized in 40 µL of freshly 
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prepared formic acid by passing the mix through a 1 mL pipette 15 times. Mixtures 
were then vortexed and incubated for 30 min at RT with agitation at 1,200 rpm. Ho-
mogenates were then supplemented in 760 µL of 1M Tris HCl (pH 8), followed by 
centrifugation at 16,100 xg for 90 min at 4°C. The supernatant was collected as formic-
acid-enriched fraction (FA). To remove any insoluble components, all enriched frac-
tions (EC, IC, MB, and FA) were centrifuged again at 16,100 ×g at 4°C for 90 min. 
Resultant minute pellets were discarded and supernatants were used for further bio-
chemical analysis. Formic-acid-enriched fractions were concentrated by vacuum cen-
trifugation (to improve protein concentrations, volume was reduced to half). Lysis buff-
ers, i.e. NP-40, TNT and RIPA lysis buffers, were filtered using a 0.2 µm syringe filter 
and were supplemented with protease and phosphate-inhibitors cocktail prior to use.  
2.2.9 Sucrose-gradient ultracentrifugation 
For the segregation of density variants of proteins, rate zonal centrifugation was ap-
plied to cerebral cortex homogenates derived from patients with rpAD, spAD, and CJD 
subtypes as well as to age-matched controls. Sucrose-density-gradient centrifugation 
was carried out following the protocol already described (Cohen et al., 2015; Zafar, 
Younas, et al., 2018). Frontal cortex homogenates, 10% w/v in tissue lysis buffer I, 
were prepared using microbeads homogenizer. Homogenates were then clarified by 
centrifugation at 500 xg for 5 min, and 400 µL were carefully layered onto the top of 
10 – 45% sucrose gradients. Gradients were manually prepared in thin wall polyal-
lomer tubes (13 x 51 mm, Beckman) by layering sucrose solutions at different dilutions 
from bottom to top. Sucrose serial dilutions (10, 15, 20, 25, 30, 35, 40, 45% w/v) were 
prepared in PBS-1% N-lauryl sarkosyl (pH 7.4). To avoid variation among the repli-
cates in an experiment, all the gradients were prepared with the same buffer batch at 
the same time. For the preparation of sucrose gradients in the thin wall polyallomer 
tubes, the tubes (sucrose layers) were frozen for 10min at -80°C after addition of each 
sucrose layer. The next layer was then added over the previous frozen layer, to avoid 
mixing of sucrose serial dilutions, the method was modified from a previously de-
scribed protocol (Luthe, 1983). Gradients were then allowed to thaw overnight at 4°C 
before use. Ultracentrifugation was performed at 50,000 rpm for 73 min at 5°C in an 
Optima TL 60 floor ultracentrifuge (Beckman Coulter) equipped with a Beckman Coul-
ter SW-55ti rotor. These conditions correspond to the adjusted proportionality constant 
k = 58.7 and angular velocity v = 5236 rad/s. Thereafter, twenty density variant 
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fractions, 200 µL each, were collected carefully from top to bottom in separate tubes 
from each sample. 
2.2.10 Preparation of protein and peptide pools from high-density gradient frac-
tions 
Equal volumes of same density gradient fractions originating from the frontal cortices 
(n=6) of different patients from each pathological cohort were pooled together to pro-
ceed to co-immunoprecipitation and mass spectrometric analysis. 
2.2.11 Co-immunoprecipitation of density variant fractions 
To study the unique interactomics signature of density variant species of PrPC oligo-
mers, high throughput co-immunoprecipitation was employed. Density variant frac-
tions were replenished with the phosphatase and protease-inhibitor cocktails, before 
the co-immunoprecipitation assay was carried out. High throughput Co-IP kits (catch 
and release HT immunoprecipitation kit, Cat. No.17-501, Merck) were used for the 
sake of assay homogeneity. High-density fractions were employed for Co-IP according 
to the manufacturer’s instructions. Together with the fractions, lysate-only controls, 
antibody-only controls and whole lysate control were also included in the assay. 
2.2.12 Proteinase K digestion 
Protein homogenates prepared in Lysis buffer II (10% w/v) containing 200 µg of pro-
teins were treated with proteinase K (PK) at a concentration of 50 µg/mL. Protein di-
gestion was carried out at 37C for 1 h, with the thermomixer set at 300 rpm orbital 
shaking. The digestion process was terminated by heating the samples at 65C for 15 
min. The digested samples were then boiled with adjusted volumes of 4x Laemmli 
buffer. Cooled-down samples were then used for SDS-PAGE together with the PK-
untreated samples (as negative controls). 
2.2.13 Silver staining 
After a thorough washing in ddH2O, the gels were incubated in a fixative solution for a 
minimum of 1 h. Fixed gels were then incubated with 50% ethanol for 20 min followed 
by incubation in 30% ethanol for another 20 min. Gels were then sensitized with sen-
sitization buffer for 1 min (with gentle shaking) and incubated in silver-staining solution 
for 20 min while being shaken. Thereafter, the gels were washed in ddH2O for 1 min 
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to remove excess stain. Gels were then incubated in the developing buffer until the 
required contrast was obtained (usually 5 min). The developing process was stopped 
by the addition of the fixative solution to the gel. Gels were washed and stored in 5% 
acetic acid for later use. 
2.2.14 Real-time quaking-induced cyclic amplification (RT-QuIC)  
Real-time quaking is a fluorometry-based assay for the determination of prion seeding 
activity. The method relies on the use of recombinant PrP peptide substrate to amplify 
the PrP seed from biological samples, i.e. brain tissue homogenate in our case. Ag-
gregated PrP seed binds with the thioflavin-T (Th-T) dye giving a fluorescence signal, 
hence establishing the measurement basis of the assay. RT-QuIC reaction buffer (85 
µL) was seeded with freshly prepared brain homogenates. Brain homogenates (10% 
w/v) were prepared in PBS (pH 7.4) supplemented with protease and phosphatase-
inhibitor cocktails. Samples were further diluted in PBS with a dilution factor of 10-3. 
Reactions were carried out in 96-well optical bottom black plates. After having been 
sealed, the plates were incubated in the FLOUROStar optima fluorometer at 42°C for 
80 h with intermittent shaking cycles (1 min, double orbital shaking, 600 rpm), followed 
by 1 min rest. Fibrillation kinetics were assessed by measuring Th-T fluorescence in-
tensity at 450 nm every 30 min. 
2.2.15 Staining of cryopreserved and formalin-fixed paraffin-embedded (FFPE) 
tissues  
Frozen tissue sections were affixed to the chuck of the cryotome using tissue tec 
(OCT). The complete process was performed without the tissue being allowed to thaw. 
Tissue sections of 5 µm thickness were obtained and were carefully transferred from 
the cryotome platform to glass slides. Tissue sections on glass slides were fixed by 
immersion in methanol for 9 min followed by immersion in acetone for 1 min. 
For paraffin-embedded blocks, frontal cortex sections were taken from buffered for-
malin-fixed hemispheres and were dehydrated in serial ethanol dilutions (10% - 
100%), replaced by xylene, and the sections were embedded in paraffin. Sections of 
2-5 µm thickness were cut using a sliding microtome and were mounted on glass 
slides after having been flattened on the water surface in a water bath set at 37°C. For 
further immunofluorescent preparations, sections were dewaxed by incubating the 
slides at 63°C, followed by incubation with xylene and rehydration by immersing in 
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alcohol serial dilutions (100%-95%-80%-50%) for 5 min each, with a final incubation 
in water for 5 min. Antigen retrieval was achieved by cooking the sections in citrate 
buffer (pH 6.0) for 1 h, followed by 30 min cooling and 1 h washing with tap water. 
Sections were exposed to UV-A and UV-B for 20 min followed by incubation with Su-
dan Black, 0.1% in 25% EtOH for 20 min as a countermeasure to autofluorescence. 
Slides were then washed in 1x PBS. Tissue sections were permeabilized with 0.2% 
Triton X-100 in 1x PBS, followed by a 30 min blocking using blocking buffer with 10% 
FBS and 1% BSA in 1x PBS. Blocking was followed by the primary antibody (diluted 
in 1% BSA-PBS) incubation at 4°C overnight. Amyloid plaques were visualized using 
mouse anti-Aβ antibodies (6E10 + 4G8; 1:100 in antibody diluent), Tau tangles were 
visualized using rabbit anti-Tau (1:100), and rabbit anti-Tau phospho-(S199 + S202) 
(1:100) antibodies. The co-localization of G2L2 and the interacting partners was ana-
lyzed using rabbit anti-growth arrest specific 2 like 2 (1:100), mouse anti-PrP SAF70 
antibody (1:100), rabbit anti-end binding protein 1 (1:100), mouse anti-actin-beta anti-
body (1:100) and mouse anti-tubulin-alpha antibody (1:100). After having been 
washed with PBS, slides were incubated for 60 min with corresponding Alexa-488 and 
Alexa-546 labeled secondary antibodies. For the nuclear staining, slides were incu-
bated with TO-PRO-3 iodide (1:1000 dilution in PBS) for 10min at RT. Finally, co-
verslips were mounted on the glass slides with Fluoromount-G and were stored at 4°C 
prior to confocal scanning. All the steps were carried out in a dark, humid chamber. 
2.2.16 Confocal laser scanning and image quantification 
Confocal laser scanning microscopy was carried out using an SPE laser-scanning mi-
croscope (Leica, Germany; 543 and 633 nm helium-neon and 488 nm argon excitation 
wavelengths) using a 63x/1.25 oil immersion lens for the localization of PrPC and other 
interacting proteins. Resulting individual images were separately analyzed for co-lo-
calization using the ImageJ (WCIF plugin) software. For two-color analysis, images 
were obtained using a dynamic range of 12 bits per pixel. Threshold Mander’s overlap 
coefficient and Pearson's linear correlation coefficient (rP) values were calculated to 
quantify fluorescence channel correlations and illustrate the strength and direction of 
the linear relationship between two fluorescence channels. Additionally, intensity cor-
relation analysis (ICA) was carried out for the channel intensities. The ICA analysis is 
based on a comparison of intensities of signal A or B along the product of the differ-
ences from the mean (PDM: product of the difference of each pixel A and B intensities 
Materials and methods 
37 
 
from their respective means as previously described (Li et al., 2004)). The resulting 
plots emphasize the high intensity stained pixels and allow the identification of protein 
pairs that vary in synchrony (positive PDM values), randomly (around 0), or inde-
pendently (negative PDM values) within the cell. 
2.2.17 Mass spectrometry-spectral counting 
2.2.17.1 Peptide digestion and extraction 
Either frontal cortex homogenates (50 µg protein per sample), density variant fractions 
(30 µL) or Co-IP eluates from density variant fractions (30 µL each) were loaded onto 
4-12% NuPAGE Novex Bis-Tris Mini gels (Invitrogen) and run into the gel for 1 cm. 
Following Coomassie staining, the protein-stained gel areas were excised, diced, and 
washed in ddH2O. After having been washed, the gel slices were reduced with reduc-
ing buffer (10 mM DTT in 100 mM NH4HCO3) by being incubated for 30 min at 56°C, 
followed by alkylation with alkylation buffer (55 mM IAA in 100 mM NH4HCO3) at RT 
in the dark for 60 min. Gel slices were then incubated in acetonitrile (ACN) for 15 
min and dried in a SpeedVac to remove excess solvent. Dried gel slices were stored 
at -20°C before further use (Atanassov & Urlaub, 2013). For mass spectrometric iden-
tification of Co-IP from whole brain homogenates, the eluates were loaded on to 12% 
SDS polyacrylamide gels and gel electrophoresis continued until the loading dye had 
reached the bottom. Gels were then silver-stained, and the silver-stained bands were 
excised and processed for the peptide extraction with the protocol detailed above.  
2.2.17.2 Peptide identification 
Peptide mixtures were concentrated on a reversed phase-C18 precolumn (20 mm x 
0.15 mm ID, self-packed with Reprosil-Pur 120 C18-AQ 3 µm material). Separation 
was achieved on a reversed phase-C18 nanoflow chromatography (Picofrit column, 
0.075 mm ID × 200 mm (New Objective, Woburn, USA)) using a 60 min linear gradient 
(5-35% acetonitrile vs. 0.1% formic acid gradient), at a flow rate of 240 nL/min on an 
Easy nLC-1000 nanoflow chromatography system (Thermo Fisher Scientific, Dreieich, 
Germany). Eluents were analyzed on a Q Exactive hybrid quadrupole/orbitrap mass 
spectrometry system instructed by Excalibur v2.4 software (Thermo Fisher Scientific). 
A top10 method in the Data Dependent Acquisition mode was implemented to carry 
out the analysis. Raw2MSM v1.17 software (Max Planck Institute for Biochemistry, 
Martinsried, Germany) was used to extract tandem mass spectra for database 
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searching. MS/MS spectra were evaluated using Mascot (Matrix Science, London, UK; 
version 2.4.1) instructed to search for UniProt/SwissProt Homo sapiens reference pro-
teome (revision 02-2017, 92,928 entries) with mass tolerances of 5 ppm for precursors 
and 0.02 Da for fragments, respectively. Methionine oxidation was considered as a 
variable post-translational modification (PTM) and cysteine carbamidomethylation as 
a fixed modification. Up to two missed cleavages were allowed. For validation of 
MS/MS based peptide and protein identifications, Scaffold software v4.8.4 (Proteome 
Software, Portland/OR, USA) was used. Peptide identifications were accepted if es-
tablished at greater than 95.0% confidence, while a minimum of two confident peptide 
identifications and a confidence threshold of 99.0% was required for protein identifica-
tions. 
2.2.18 SWATH-MS (Sequential Windowed Acquisition of All Theoretical Frag-
ment Ion Mass Spectra)-based global proteomics 
2.2.18.1 Library preparation 
For the generation of a peptide library, equal amount aliquots from each sample were 
pooled to a total amount of 80 µg and separated into eight fractions using a reversed 
phase spin column (Pierce High pH Reversed-Phase Peptide Fractionation Kit, 
Thermo Fisher Scientific). 
Peptides resulting from tryptic digestion were analyzed on an Eksigent nanoLC425 
nanoflow chromatography system associated hybrid triple TripleTOF 5600+, quadru-
pole-TOF mass spectrometer (equipped with a Nanospray III ion source). Parameters 
for ionization were set as follows: ionspray voltage 2400 V, interface heater tempera-
ture 150°C, and sheath gas setting 12. Analyst TF 1.7.1 software build 1163 (AB 
Sciex) was used to instruct the system. Peptides were dissolved in loading buffer (2% 
acetonitrile, 0.1% formic acid in water) to a final concentration of 0.3 µg/µL. For each 
analysis, 1.5 µg of digested protein were concentrated on a self-packed precolumn 
(0.15 mm ID x 20 mm, Reprosil-Pur120 C18-AQ 5 µm, Dr. Maisch, Ammerbuch-En-
tringen, Germany), followed by separation on an analytical RP-C18 column (0.075 mm 
ID x 250 mm, Reprosil-Pur 120 C18-AQ, 3 µm, Dr. Maisch) using a 100 min linear 
gradient of 5%-35 % acetonitrile-0.1% formic acid at a flow rate of 300 nL/min. Quali-
tative LC-MS/MS analysis was performed using a Top30 data-dependent acquisition 
method with an MS survey scan of m/z 380–1250 accumulated for 250 ms at a 
Materials and methods 
39 
 
resolution of 35,000 full width at half maximum (FWHM). MS/MS scans of m/z 180–
1500 were accumulated for 100 ms at a resolution of 17,500 FWHM and a precursor 
isolation width of 0.7 FWHM, resulting in a total cycle time of 3.4 s. Precursors ions 
with a threshold MS intensity of more than 200 cps and with charge states 2+, 3+, and 
4+ were selected for MS/MS, and the dynamic exclusion time of 15 s was set. MS/MS 
activation was achieved by CID by the manufacturer’s default rolling collision energy 
settings using nitrogen as a collision gas. Two technical replicates per reversed phase 
fraction were analyzed to construct a spectral library. 
2.2.18.2 Quantitative SWATH measurement 
For quantitative SWATH analysis, MS/MS data were acquired using 100 variable size 
windows (Zhang et al., 2015) across the 400-1200 m/z range. Fragments were pro-
duced using rolling collision energy settings for charge state 2+, and fragments ac-
quired over an m/z range of 180–1500 for 40 ms per segment. Including a 250 ms 
survey scan, this resulted in an overall cycle time of 4.3 s. Two replicate injections 
were acquired for each biological sample. Protein identification was achieved using 
ProteinPilot Software version 5.0 build 4769 (AB Sciex) at “thorough” settings. A total 
of 152,341 MS/MS spectra from the combined qualitative analyses were searched 
against the UniProtKB Homo sapiens reference proteome (revision 02-2017, 92,928 
entries) augmented with a set of 51 known common laboratory contaminants to identify 
1,756 proteins at a false discovery rate (FDR) of 1%. Spectral library generation and 
SWATH peak extraction were achieved in PeakView Software version 2.1 build 11041 
(AB Sciex) using the SWATH quantitation microApp version 2.0 build 2003. Following 
retention time correction on endogenous peptides spanning the entire retention time 
range, peak areas were extracted using information from the MS/MS library at an FDR 
of 1% (Lambert et al., 2013). The resulting peak areas were then summed to peptide 
and finally protein area values, which were used for further statistical analysis.  
2.2.19 Statistical analysis  
Graphpad Prism 6.0 was used for basic statistical analysis. For immunoblotting, den-
sitometric analysis of western blots and 1-DE gels was carried out using Lab image 
(version 2.7.1 Kapelan, Leipzig, Germany) software. Results in the current study were 
obtained from four independent experiment sets and are expressed as mean ± S.E.M 
(standard error of the mean). For prion protein-interactome identification (Co-IP mass 
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spectrometric analysis) of frontal cortex lysates, MS/MS readings were carried out in 
duplicates for four biological replicates for each disease subtype and non-demented 
controls (n=4). Likewise, interactome of high-density prion oligomers was carried out 
by Co-IP mass spectrometric analysis of IP eluates in technical replicates (n=2). 
Global proteomic profiling of high-density fraction pools by mass spectrometric spec-
trum counting was also performed in technical replicates (n=3). Principle component 
analysis, z-score normalizations and one-way ANOVA were carried out using Perseus 
(version: 1.6.1.3). For hierarchical clustering, gplots R-package was used. Statistical 
significance was considered for p-value < 0.05. No adjustments for multiple testing 
were performed in this pilot study. 
2.2.20 Bioinformatic analysis 
UniProt/SwissProt database (release 02/14 filtered for Homo sapiens entries) was 
used for functional enrichment of the detected proteins from the MS/MS analysis. Pro-
tein candidates from high-density fraction datasets and global proteome datasets were 
manually grouped in modules, based on the UniProt/SwissProt database annotations, 
representing a singular physiological category for proteomics  
Pathway enrichment analysis of HDP-ligands was performed using the Bioconductor 
clusterProfiler package (Yu, Wang, Han, & He, 2012). Reactome pathway database 
for Homo sapiens was used as a reference database (Fabregat et al., 2018). 
Protein-protein interactions were structurally visualized by in silico analysis using a 
web-based tool, the ZDOCK server-version 3.0 (Pierce et al., 2014; Pierce, Hourai, & 
Weng, 2011). Three-dimensional reference structures for the proteins studied were 






Diseases are usually outcomes of multiplex physiological variations at biochemical 
and metabolic strata. Minor differences even in these physio-alterations result in the 
broad spectrum of variability even in a single disease giving rise to subtypes.  
Likewise, differences have been discussed for the progression rate amongst patients 
with Alzheimer’s disease, leading to the classification of non-genetic sporadic LOAD 
cases in two categories, i.e. classical cases (abbreviated as spAD in the study) with a 
disease span of ~8 years and cases with a higher progression rate and shorter survival 
time ~4 years (abbreviated as rpAD in the study). In the current study, we aim to define 
the mechanistic differences behind the variation in the progression rate. 
3.1 Characterization of the rpAD cohort 
The present experimental study included the characterization of the progression rate 
variants of the AD, using established hallmarks and signal transduction pathways, uti-
lizing a multitude of techniques including histochemistry, immunoblotting analysis, and 
SWATH-MS mass spectrometry. 
3.1.1 Localization of amyloid plaques and Tau tangles 
Alzheimer’s subtype specific pathological features were studied using immunofluores-
cence microscopy to identify differences between plaque profiles and Tau tangles typ-
ical for sporadic and rapid Alzheimer’s cases.  
3.1.1.1 Amyloid plaques  
Anti-amyloid β antibodies (6E10 and 4G8) were used together to visualize the amyloid 
plaques. Microscopic visualization of amyloid plaques revealed a difference in the 
pathological presentation. A trend towards decrease in the Aβ-plaque diameter was 
observed in the rpAD cortical sections compared to that of spAD. In rpAD cortices, a 
significant increase in the frequency of Aβ plaques was observed in comparison to the 





Figure 10: Characteristic presentation of amyloid plaques in spAD and rpAD frontal 
cortex tissues. A) Amyloid beta localization was visualized by using anti-amyloid β anti-
bodies (4G8 and 6E10 mixture) shown in A.a and A.b for spAD and rpAD respectively. A.c 
and A.d correspond to the nuclear stain for spAD and rpAD respectively. A.e and A.f show 
merge images for both channel and A.g and A.h show the higher magnification micrographs 
for spAD and rpAD, respectively. Frontal cortex tissues from spAD showed typical plaque 
structure, whereas a higher number of smaller plaque populations was observed in frontal 
cortex tissues from rpAD. B-C) Statistical analysis was performed using cortical sections 
from rpAD (n=3) and spAD (n=3) patients, p-values were calculated using Student t -test. 
Counting f Aβ plaques was performed in the randomly selected regions of interest with 
length and width measuring 200 µm each. Scale bars in sections a-f = 250 µm and scale 
bars in sections g, h = 50 µm. *p < 0.05, **p < 0.005,  
3.1.1.2 Tau tangles  
Neurofibrillary Tau tangles (NFTs) constitute one of the highly differentiating patholog-
ical features of Alzheimer’s disease. The NFTs form because of an accumulation of 
abnormally hyperphosphorylated Tau protein in neurons. To study NFTs, frontal cortex 






Figure 11: Localization of Tau and hyperphosphorylated Tau in Alzheimer’s sub-
types. Distribution of neurofibrillary tangles was assessed in the frontal cortex of rpAD and 
spAD brain cortex, using anti-Tau antibody (A) and anti-Tau phospho-(S199, S202) anti-
body (B). Scale bars correspond to 50 µm. No significant differences could be seen in the 
distribution and size between spAD and rpAD frontal cortices. Statistical significance was 
calculated using Student t-test.  
Immunofluorescence microscopy for Tau revealed no significant differences in the 
NFT profiles, although, a trend was observed towards relatively smaller NFT clusters 
in the rpAD when compared to spAD cortices. Likewise, no significant differences were 
observed between NFT profiles for spAD and rpAD frontal cortices, when observed 
after immunolocalization using anti-p-Tau antibody. And a similar trend towards 




3.1.2 Expressions of amyloid-β and hyperphosphorylated Tau 
The pathological development of senile plaques and Tau tangles associated with the 
AD is a result of differential APP cleavage, resulting in higher concentrations of amy-
loid-β species, and a higher degree of hyperphosphorylated Tau protein, respectively. 
Expression of total Tau, p-Tau, and amyloid-β was biochemically assessed using im-
munoblot analysis to estimate differences between the groups of rpAD and spAD pa-
tients. The densitometric analysis revealed no significant difference in the total 
amounts of Tau, p-Tau and the ratio of p-Tau to Tau, although a non-significant relative 
decrease in Tau phosphorylation could be noted for rpAD cases (Figure 12, A&C). 
Various low molecular weight amyloid-β oligomers, including dimers, trimers, hex-
amers, and dodecamers (Aβ-56*, a 56 kD species) were quantified in rpAD, spAD and 
controls. However, no significant differences in expression could be identified among 
the three groups (Figure 12, B).  
 
Figure 12: Expression of Total Tau, p-Tau, and Amyloid-β. Expression of Tau, phos-
pho-Tau (S199) and amyloid-β was assessed in frontal cortex (FC) of rapidly progressive 
Alzheimer’s (rpAD) samples in comparison to age-matched sporadic Alzheimer’s disease 
(spAD) patients and non-dementia controls. A) Representative blots for Tau, p-Tau. B) 
Representative immunoblots for various amyloid-β species. C-D) Densitometric analysis 
for the immunoblots for spAD cases n=7, rpAD cases n=7 and controls n=7, showed no 
significant differences in the levels of Tau, pTau, and amyloid beta oligomer species. Sta-
tistical significances were calculated using one-way ANOVA and intergroup comparisons 




amyloid-beta, CTF-β: C-terminal fragment-β of the amyloid precursor protein, Aβ-56*: do-
decamer of Aβ at 56 kDa. 
3.1.3 Differential kinome 
Protein kinases are major contributors in the regulation of cellular machinery. Altera-
tions in many kinases and their respective signal transduction pathways have been 
linked to neurodegeneration in general and Alzheimer’s disease as well. We investi-
gated extracellular signal-regulated kinases 1/2 (ERK 1/2), protein kinase B (AKT), 
mitogen-activated protein kinases p38 (p38), nuclear factor kappa-light-chain-en-
hancer of activated B cells (NFkB), glycogen synthase kinase 3-β (GSK3B) and re-
spective phosphorylated forms using immunoblotting. The expression of calcium/cal-
modulin-dependent protein kinase type II (KCC2), myosin light chain kinase (MYLK), 
dual specificity mitogen-activated protein kinase-kinase 4 (MP2K4), pyruvate kinase 
PKM (KPYM), phosphatidylinositol 5-phosphate 4-kinase type-2 alpha (PI42A), pro-
tein kinase C (KPC), mitogen-activated protein kinase 1 (MK01) and proto-oncogene 
tyrosine-protein kinase Src (SRC) was assessed using SWATH-MS (DIA MSMS anal-
ysis).  
 
Figure 13: Expression regulation of kinases with known relevance to neurodegener-
ative diseases. A) Representative immunoblots for the expression of AKT, phospho-AKT, 
ERK, phospho-ERK, p38, phospho-p38, NFkB, phospho-NFkB, GSK3B and phospho-
GSK3B were assessed from frontal cortex (FC) homogenates of rpAD patients in compar-
ison to age and stage-matched spAD patients and controls. GAPDH was used as a loading 
control. B) Densitometric analysis based on rpAD samples (n=7), spAD patients (n=7) and 
controls (n=6), showed no significant differences in phosphorylated forms of the kinases 
mentioned. Statistical significance was calculated with one-way ANOVA followed by Tukey 




The kinases studied with immunoblot analysis showed no significant differences 
among the study groups for active (phosphorylated) ERK 1/2, AKT, p38, NFkB, and 
GSK3-β. The densitometric analysis for the immunoblots exhibits a vast variation 
among the sample cohorts used (Figure 13).  
Total expression of CaMKII subunit gamma was found increased in the spAD com-
pared to both rpAD and non-dementia controls in the SWATH-MS analysis. No ob-
servable significant differences were seen in MYLK, MP2K4, KPYM, PI424, KPC, 
MK01 and SRC kinases expression (Figure 14). 
 
Figure 14: Expression analysis of selected kinases using SWATH-MS. MYLK, MP2K4, 
KPYM, PI42A, KPC, KCC2, MK01 and SRC were assessed using SWATH-MS. Relative 
quantitation of selected candidates did not reveal any significant differences among spAD 
(n=3), rpAD (n=3) and controls (n=3) except for increased KCC2G expression in spAD. 
Statistical significance was calculated with one-way ANOVA followed by Tukey post-hoc 
test to compare all paired interactions. *p < 0.05. 
3.2 Differential regulation of prion protein metabolism 
Alzheimer’s disease cases with rapid progression have been shown to have higher 
levels of low molecular weight oligomeric species of amyloid-β oligomers. Prion protein 
becomes an interesting candidate for the study, due to its involvement in the seques-
tering of amyloid-β oligomers. We analyzed the expression of total prion protein (PrP) 
and relative expression of glycosylated variants, the distribution of PrP in extracellular 
and intracellular environments in cerebral cortex samples, followed by a study of con-
formation variants of PrP and respective protein ligands. 
3.2.1 Subtype-specific alterations in PrP expression 
PrPC exists in three isoforms, namely di-glycosylated (DG), monoglycosylated (MG) 


































































controls was estimated by immunoblot using SAF70 anti-PrP antibody (epitope 155-
161 aa-residues). Total PrPC expression exhibited no significant differences among 
AD subtypes and controls in our cohort. Conversely, a decrease in total PrP has been 
reported in Alzheimer’s cases (Whitehouse et al., 2013). After normalizing expression 
of each glycoform to the respective total PrP expression, a small, but consistent and 
statistically significant decrease in DG-PrP expression was observed in rpAD group.  
 
Figure 15: Differential expression of di-glycosylated PrP isoform. A) PrP expression 
was measured in spAD and rpAD using anti-PrP SAF70 antibody for immunoblotting and 
GAPDH as a loading control. B) Densitometry analysis from four independent immunoblot-
ting experiments using control (n=10), spAD (n=15), and rpAD (n=8) cases. Statistical sig-
nificance was calculated with one-way ANOVA followed by Tukey post-hoc test for inter-
group comparisons. *p < 0.05, **p < 0.001; DG, di-glycosylated isoforms; MG, mono-gly-
cosylated isoforms; UG, un-glycosylated isoforms. 
Lowest expression was seen in rpAD cases, followed by spAD. The relative expres-
sion levels of MG-PrP and UG-PrP were not significantly different among the study 
cohorts. 
3.2.2 Differential localization of PrP isoforms in cerebral tissue 
Relative expression of PrPC was analyzed in enrichment fractions of extracellular, cy-




levels of extracellular PrP isoforms in both AD subtypes in comparison with controls. 
Intergroup comparison of rpAD and spAD showed a significant reduction in Ex-PrP 
levels in rpAD. The rpAD cases also showed a statistically significant decrease in PrP 
levels in the cytosolic enriched proteins. However, there were no significant intergroup 
differences in the PrPC from membrane enriched proteins. In the extracellular enrich-
ment fragment, a lower abundance of DG-PrP was also observed (Figure 16). 
 
Figure 16: Decrease in shed-PrP in extracellular enrichment fraction. Expression of 
prion protein was assessed using anti-PrP antibody (SAF70) in homogenates enriched for 
extracellular, cytosolic and membrane-bound proteins, represented as EX-PrP, Cyt-PrP, 
and MB-PrP, respectively. B & C) Densitometric analysis from four independent immunob-
lotting experiments using controls (n=6), spAD (n=6), and rpAD (n=6) cases. Data are 
shown as average ± SEM in graphs. Statistical significance was calculated with one-way 
ANOVA followed by the Tukey post-hoc test for intergroup comparisons. DG, di-glycosyl-
ated isoforms; MG, mono-glycosylated isoforms; UG, un-glycosylated isoforms; *p < 0.05, 
**p < 0.005, ***p < 0.001. 
Subtype-specific differential cellular localization of PrPC was also seen in rpAD frontal 
cortex tissues. A significant degree of PrPC-nuclear co-localization was seen in the 
neuronal cells from cerebral cortices of Alzheimer’s disease cases. The extent of PrPC-
nuclear localization was seen to be significantly higher in rpAD cases when compared 
to spAD cases, represented by the overlap of nuclear and PrP channels in ICA (inten-





Figure 17: Characteristically distinct PrPC-Nuclear localization in spAD and rpAD hu-
man brains. A-C) Colocalization of PrPC and nuclear stains in the frontal cortex brain re-
gion in controls (A), spAD (B), and rpAD (C) patients, is shown using SAF70 anti-PrP anti-
body. Corresponding higher magnification areas (D-F) show higher extent of nuclear and 
PrP overlap in rpAD. G, I, and K) ICA plots for Con, spAD and rpAD respectively. A greater 
degree of overlap/colocalization can be seen between the PrP and nuclear channels in the 
rpAD ICA plot. H, J, and L) Representative correlation plots corresponding to Con, spAD 
and rpAD, respectively. Highest channel overlap can be observed in the scatter plot for 
rpAD (L). Scale bars in A-C: 75 µm, in D-F: 3.5 µm. 
3.2.3 Characteristic PrPC interactome identification in spAD and rpAD human 
brains 
PrP-interacting proteins were isolated from rpAD, spAD and control frontal cortex tis-
sues using Protein G coupled to super magnetic Dynabeads® after binding anti-prion 
SAF70 and SAF32 antibodies, separately. Co-IP eluates were resolved on SDS-
PAGE, stained silver (Figure 18) and whole lanes from spAD, rpAD, and control eluate 




identified with ESI/Q-TOF MS/MS. Among the identified PrP-interacting proteins, both 
known and novel PrP-interacting partners could be observed (Table 12), listing fifteen 
proteins as interacting partners of PrP. Two of these interactors, namely histone H2B 
type 1- B (H2B-1B) and zinc alpha-2 protein (ZAG), were uniquely found with PrP 
isolated from rpAD cases. However, three proteins, i.e., tubulin beta 2C, synaptojanin-
1, and synaptopodin, showed no potential interaction with the PrP isoform from spAD 
and rpAD cases and appeared to bind to PrP specifically in the controls. Interestingly, 
one protein, namely myelin P2, was solely isolated as the binding partner with the PrP 
isoform in spAD samples. Four interacting proteins, i.e., peroxiredoxin 1, four-and-half 
LIM domains protein 1, transketolase variant (fragment), and the basic myelin protein, 
were found in both spAD and rpAD cases. Furthermore, four PrP binding proteins, 
ribonuclease UK114, fructose-bisphosphate aldolase A and lysozyme C, were found 
in common in the AD and non-demented healthy controls; and lastly, synapsin-1 and 
myelin proteolipid peptide were found to interact with PrP in all cases. 
 
Figure 18: Characteristic PrP interactome identification in spAD and rpAD human 
brains. PrP-interacting partners isolated from spAD, rpAD, and control cases by using 
SAF32 and SAF70 PrP Protein G coupled to magnetic Dynabeads. The bands were ex-
cised, digested in-gel, and proteins were identified by ESI/Q-TOF MS/MS mass spectrom-




Table 12: List of prion protein-interacting proteins in rpAD and spAD as determined 
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rpAD, rapid progressive Alzheimer’s disease; spAD, sporadic Alzheimer’s disease; Cont, 
controls (non-demented); Nu, nucleus; Pm, plasma membrane; Ee, extracellular exosome; 
C, cytoplasm; Ms, myelin sheath; Fa, focal adhesion; Mm, myelin membrane; Cs, cytoplas-
mic side; Cm, cell membrane; Cp, clathrin coat of coated pit; Cj, cell junction, Ck, cytoskel-
eton; S, secreted; Ga, Golgi apparatus; Sv, synaptic vesicle. The localization of proteins 
and accession number are assigned as in the ExPASy protein database and Uniprot data-
base, respectively. Relevance for AD, prion and PrP ligand were also established by a 
UniProt database search. 
3.2.4 Confirmation of unique rpAD-specific PrP interactors 
Among the identified PrP-binding proteins, interactions of zinc alpha-2 glycoprotein 
and peroxiredoxin-1 were confirmed by reverse IP experiments, followed by immunob-
lotting. The ZAG-PrP binding, specific for rpAD cases and PRDX1-PrP binding specific 
for both sporadic and rapidly progressive forms were confirmed by Co-IP using Anti-
ZAG and Anti-PRDX1 antibodies followed by immunoblotting (Figure 19). 
 
Figure 19: Reverse-IP and immunoblot verification of PrP-ZAG interaction. A) IP elu-
ates were immunoblotted against PrP and ZAG by using specific monoclonal antibodies. 
ZAG and GAPDH immunoblotting analysis in spAD, rpAD, and control samples were used 
as loading controls. B and C) correspond to densitometry analysis from four independent 
(± SEM) IP eluate immunoblotting experiments with controls (n=10), spAD (n=10), and 
rpAD (n=10). The significance was calculated with one-way ANOVA and Tukey post-hoc 




The possible interaction of PrP and ZAG was also corroborated by co-immunofluores-
cence using ZAG and PrP specific antibodies in frontal cortices from rpAD patients. 
Image analysis using ICA (intensity correlation analysis) revealed a high overlap be-
tween the channel intensities of PrP and ZAG in rpAD (Figure 20. A). We also con-
firmed in silico the probability of PrPC-ZAG interaction using ZDOCK 3.0 (Figure 20. 
B). ZDOCK 3.0 relies on the crystalline structures of proteins and calculates the bio-
chemical feasibility of interaction between specific proteins of interest. 
 
Figure 20: Subtype-specific colocalization of PrPC and ZAG in frontal cortex region. 
A.a) Representative micrograph showing co-localization of PrP and ZAG in the frontal cor-
tex of rpAD brain tissues using SAF70 anti-prion antibody (red signal) and ZAG antibody 
(green signal). Higher magnification shows overlapping (yellow signal) of PrP and ZAG in 
the frontal cortex brain region of rpAD brains. ICA plot (A.b) and scatter plot (A.c) also 
illustrate the interaction between PrP and ZAG in rpAD brain samples. B) In Silico prediction 
of protein-protein interaction between PrP and ZAG shows PrP (grey) and ZAG (pink) in-
teracting sites by ZDOCK 3.0, and the molecule represents its corresponding centered ori-
entation.  
3.3 Identification of disease-specific PrP oligomers 
The differences between the disease subtype-specific PrP-interactome lead us to hy-
pothesize the possibility of various subtype-specific PrP oligomers, as PrP is known 
for the conformational instability in transmissible spongiform encephalopathies, and 
for its potential to oligomerize (C. Kim et al., 2011). To study the disease-specific var-
iants, we relied on the density gradient centrifugation using (10-45%) sucrose, 1% 
sarkosyl-PBS-step gradient. Centrifugation was carried out at 50,000 rpm, 5°C, after 




Creutzfeldt Jakob disease (sCJD) frontal cortex samples as positive controls to the 
study. The experiment design is shown in the figure below (Figure 21). 
 
Figure 21: Experimental setup for isolation and characterization of disease-specific 
PrP conformers. Density gradient centrifugation using (10-45%) sucrose, 1% sarkosyl-
PBS-step gradient was used for the separation of density variants. Centrifugation was car-
ried out at 50,000 rpm at 5°C. Twenty density fractions were taken from top to bottom 
(lighter to dense) and were used for downstream biochemical assays and analyses. 
From the immunoblotting of high-density fractions, we were able to identify the differ-
ential high-density PrP (HDP) oligomers in high-density fractions specific for rpAD, 
resembling that of sCJD PrP conformers. These HDPs were identified in the high-
density fractions ranging between fraction thirteen and seventeen in rpAD cases (Fig-
ure 22). 
 
Figure 22: Resolution of characteristic density variant PrP oligomers by sedimenta-
tion centrifugation in sucrose gradient in spAD and rpAD human brain frontal corti-
ces. A) The gradient fractionation profile of PrP particles from spAD, rpAD, sCJD and con-
trols after separation by ultracentrifugation in a sucrose gradient. Fractions collected from 




Densitometric analysis from four independent immunoblotting experiments (average ± 
SEM). The significance was calculated with one-way ANOVA and Tukey’s post-hoc test 
(*p < 0.05). AU are arbitrary units. Each blot contains twenty fractions from only one sam-
ple. 
Results demonstrated PrP presence as detected in all the density fractions of sCJD 
cortex lysates. An overall outlook of PrP presence in disease subtypes is summarized 
in Figure 23. 
 
Figure 23: Profile of high density PrP (HDP) oligomer occurrence in cortical isolates 
of rpAD, spAD, and sCJD. HDP oligomers were uniquely detected from the density frac-
tions 13 to 17 in rpAD subtype, overlapping with the HDPs from CJD. 
3.3.1 Proteinase-K (PK) resistance and absence of seeding activity 
Due to the overlap of sCJD and rpAD high-density PrP conformers, it could be as-
sumed that the PrP conformers from rpAD may attain some properties of sCJD PrP, 
leading to the formation of high-density oligomers. Hence, we analyzed the PK re-
sistance and the prion seeding activity in brain frontal cortex homogenates. We also 
assessed the seeding potential of PrP conformers in the rpAD-specific high-density 
fractions. PK-resistant PrP species could not be identified from the AD subtypes and 
the control cohorts.  
In the Th-T based, real-time quaking-induced cyclic amplification (RT-QuIC) assay, no 
prion seeding activity was seen in the brain frontal cortex lysates in spAD, rpAD, and 
controls in comparison to that of sCJD. Corresponding observed relative fluorescence 
units (RFU) values were lower than the cut-off i.e. 2.0x104. For the sCJD samples, we 





Figure 24: PK resistance and prion seeding activity in rpAD. A) Proteinase-K (PK) di-
gestion was carried out for brain cortical homogenates from rpAD, spAD and control 
groups. PrP signal was detected via immunoblotting using anti-prion (SAF70) antibody. 
Brain homogenates in wells indicated with (-) were not treated with PK, conversely wells 
marked with (+) contain brain homogenates after PK digestion. No PK resistance was iden-
tified from the sporadic and rapidly progressive Alzheimer’s frontal cortex samples. B) Den-
sitometric analysis was carried out from four independent immunoblotting experiments in-
cluding rpAD (n=6), spAD (n=7) and controls (n=9) groups. Data are represented as aver-
age ± SEM. The significance was calculated with pairwise t-test between the PK-treated 
and untreated frontal cortex lysates (*p < 0.001). C) Prion seeding activity, from the frontal 
cortex lysates of rpAD (n=6), spAD (n=7) and controls (n=9) was measured against that of 
sporadic Creutzfeldt-Jakob disease (sCJD) (n=5), using real-time quaking induced cyclic 
amplification. The rpAD samples exhibited no seeding activity like spAD and control co-
horts. 
Likewise, no prion seeding was detected in the high-density prion (HDP) variants from 
rpAD, but the HDPs from sCJD samples resulted in almost typical RT-QuIC curves 
(Figure 25).  
 
Figure 25: Absence of seeding activity in high-density PrP (HDP) oligomers isolated 
from rpAD. Prion seeding activity, from the high-density fractions after the density gradient 
ultracentrifugation of frontal cortex lysates from spAD (n=7), rpAD (n=6) and controls (n=9) 
was assessed against sCJD frontal cortex lysates, using RT-QuIC. High-density Prion pro-





3.4 Proteomic characterization of disease subtype-specific high-
density fractions 
To analyze the overall subtype-specific proteomic profile in high-density fractions, den-
sity fractions ranging from fraction 12 to 17 were pooled using six biological replicates 
for each disease subtype separately, except for sCJD-VV2, where experiments with 5 
biological replicates were performed (fraction 12 of all biological replicates from the 
same group were pooled, similarly, the rest of the fraction pools were also prepared). 
Resultant peptide pools were subjected to high-resolution MS/MS analysis (Figure 26). 
 
Figure 26: Preparation of subtype-specific pools of high-density fractions and down-
stream high-resolution MS/MS analysis. 
In total, 1212 proteins were identified at decoy FDR <1%, with a protein threshold of 
99% and a minimum of 2 peptides. Peptide counts for the high-density fraction pools 
showed a gradual decrease from fractions twelve to seventeen in rpAD and controls. 
However, in the case of AD subtypes and sCJD subtypes, the decline in the peptide 
counts was not uniform. In spAD, the overall peptide counts remained steady in frac-
tions fifteen to seventeen, and in sCJD subtypes, the peptide counts rose again, the 
fractions ranging from fifteen to seventeen showing the higher concentration of high-





Figure 27: Dynamic range of detected peptides in the high-density fraction pools of 
disease subtypes. Sample pools were prepared from HDFs of rpAD (n=6), spAD (n=6) 
and sCJD-MM1 (n=6), sCJD-VV2 (n=5), and controls (n=6). MS/MS analysis was carried 
out in triplicates for each pool of high-density fractions. C12 to C17: HDF pool-12 to 17 from 
Con; A12 to A17: HDF pool-12 to 17 from spAD; R12 to R17: HDF pool-12 to 17 from rpAD, 
MM1-12 to MM1-17: HDF pool-12 to 17 from sCJD-MM1, and VV2-12 to VV2-17: HDF 
pool-12 to 17 from sCJD-VV2.  
3.4.1 Disease subtype-specific clustering 
Spectral counts for each high-density fraction proteome were normalized by the total 
spectra reads detected for the respective fraction, to overcome the protein loading 
variations in the mass spectrometric analysis. Averaged normalized spectral counts 
were then used to perform hierarchical clustering analysis, based on dissimilarity 
based-agglomerative clustering. As an outcome of clustering analysis, we were able 
to differentiate the disease subtype-specific clusters for controls and spAD, separate 
from the rpAD and sCJD subtypes. The cluster profiles of controls and spAD fractions 
showed close resemblance. However, the intergroup resemblance of sCJD subtype-
specific fractions was also high. The rpAD fraction proteomes presented the group 
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Figure 28: Hierarchical clustering defining the inter-closeness of subtype-specific 
high-density fractions. Clustering was performed using dissimilarity based-agglomerative 
grouping as an index of distance measurement. C12 to C17: HDF pool-12 to 17 from Con; 
A12 to A17: HDF pool-12 to 17 from spAD; R12 to R17: HDF pool-12 to 17 from rpAD, 
MM1-12 to MM1-17: HDF pool-12 to 17 from sCJD-MM1, and VV2-12 to VV2-17: HDF 
pool-12 to 17 from sCJD-VV2.  
Principle component analysis, using the averaged normalized spectral counts of HDF 
proteomes, also resulted in the clustering that resembled the clustering pattern ob-
tained via dissimilarity based-agglomerative clustering. The HDFs from rpAD pools 
clustered separately from that of spAD, controls, and sCJD. Small differences among 
the HDFs of CJD-MM1 and that of CJD-VV2, clustered them close together except for 
MM1-12. Like hierarchical clustering, (Figure 29 A). 
Principle component loadings (Figure 29 B) gave an interesting insight that the protein 






Figure 29: Subtype-specific relationships between disease variants defined by pro-
teomic signatures of HDFs. A) Graphical representation of the degree of closeness be-
tween the disease-specific HDFs as determined by PCA. B) Graphical presentation of prin-
ciple component loadings for PC-1 (principle component-1) and PC-2 (principle compo-
nent-2). C12 to C17: HDF pool-12 to 17 from Con; A12 to A17: HDF pool-12 to 17 from 
spAD; R12 to R17: HDF pool-12 to 17 from rpAD, MM1-12 to MM1-17: HDF pool-12 to 17 
from sCJD-MM1, and VV2-12 to VV2-17: HDF pool-12 to 17 from sCJD-VV2. 
3.4.2 Subtype-specific reference global proteome 
To verify the fact that the proteomic alterations in HDFs result from differential distri-
bution in the density gradients and are not due to differences in expression, we in-
cluded a comparative global proteomic dataset using sequential windowed acquisition 
of all theoretical mass spectra (SWATH-MS) for frontal cerebral cortices of rpAD (n=3), 
spAD (n=3), DLB (n=3) and controls (n=3). Rapid progressive dementia with Lewy 
bodies (n=3), DFTL (n=3) and SVD (n=3) were also included in the SWATH-MS based 
proteomics as positive controls of rpAD. In total, 1548 proteins were detected at 1% 
FDR in the global proteomics dataset, and their corresponding SWATH-MS values 
were measured for protein quantification and statistical/bioinformatic analyses. 
3.4.3 Evaluated physiological domains  
From the HDFs’ proteomic dataset, proteins of related physiological activities were 




subtypes. From the perspective of neurodegeneration, we narrowed down our study 
to proteopathic proteins, cellular protein degradation machinery, ras-related proteins, 
cytoskeleton, and chaperones. 
3.4.3.1 Proteopathic burden 
Neurodegenerative disorders are associated with proteopathies (diseases arising due 
to conformational transition in certain proteins leading to subtle functional variations). 
Proteopathic proteins were detected in abundance in the HDFs. Overall, the expres-
sion of proteopathic proteins was the highest in sCJD (MM1 and VV2) HDFs, followed 
by those of rpAD (Figure 30). 
 
Figure 30: Elevated proteopathic burden in rpAD in comparison to that of spAD. The 
proteopathic proteins are found to be most abundant in the sCJD-specific HDFs, followed 
by rpAD-HDFs. A discrete trend in the HDF levels of proteopathic proteins was observed, 
with highest expression in sCJD-subtypes and lowest in Con. F12‒F17: HDF pool 12 to 17. 
The sCJD fractions showed high relative abundances for most of the detected pro-
teins, including glial cell fibrillary acidic protein (GFAP), serpins, apolipoprotein 




hemoglobin subunits (HBA, HBB, and HBD). Interestingly, certain proteins were spe-
cifically abundant in rpAD-HDFs including synuclein isoforms and fibrinogen chains 
compared to that of spAD, sCJD and controls (Figure 30).  
In the SWATH-MS proteomic dataset, no significant differences were detected in the 
expression levels of respective proteins, showing that the variations in the HDFs’ pro-
teome do not result from native subtype-specific alterations of these proteins. Only 
GFAP was found to be significantly natively upregulated in rpAD samples in compari-
son to spAD, controls and other rapid dementias included in SWATH-MS-based global 
proteomics (Figure 31). There was no significant difference in the abundance of GFAP 
in HDFs of rpAD, spAD and controls, suggesting the involvement of GFAP in other 
physiological functions.  
 
Figure 31: Expression of disease-specific proteopathic proteins. Expression of prote-
opathic proteins as estimated by SWATH-MS-based global proteomics for spAD (n=3), 
rpAD (n=3), DLB (n=3), rDLB (n=3), D-FTL (n=3), SVD (n=3), and controls (n=3).  
3.4.3.2 Protein degradation machinery 
Proteins associated with protein degradation machinery were also detected in the 
HDFs proteome and a certain trend could be seen in their inter-group abundances. 
The peptide counts of ubiquitin-60S ribosomal protein L40 (UBA52), polyubiquitin-B 
(UBB) and ubiquitin-40S ribosomal protein S27a (RPS27A) domains were observed 
to be significantly decreased in rpAD HDFs in comparison to spAD fractions, where it 
was lowest in controls followed by sCJD subtype HDFs. Ubiquitin-like modifier-activat-
ing enzyme (UBA1) and ubiquitin carboxyl-terminal hydrolase 5 (USP5) appeared to 




abundant in rpAD-specific HDFs. However, HDF levels of proteasomal subunits are 
significantly higher in sCJD subtype in comparison to AD-subtypes (Figure 32, A). 
 
Figure 32: Dysregulations of protein degradation machinery. A) Heatmap representing 
the differences in relative concentrations (z-scores) of proteins associated with ubiquitin 
and proteasomal regulation. B) Global proteome expression levels of ubiquitin and pro-
teasomal proteins (expression estimated by SWATH-MS) for spAD (n=3), rpAD (n=3), DLB 
(n=3), rDLB (n=3), D-FTL (n=3), SVD (n=3), and controls (n=3). F12‒F17: HDF pool 12 to 
17. 
In global proteome, we could detect multiple ubiquitin-associated proteins and pro-
teasomal subunits, but there were no significant differences in the expressions of the 
detected proteins (Figure 32. B). 
3.4.3.3 Ras-related proteins 
Multiple ras-related proteins including rab proteins, rap proteins, and ral proteins were 




subtypes studied. Significantly high levels of ras-related proteins were observed pre-
dominantly in the sCJD-subtype-specific fractions in comparison to controls and AD 
subtypes. However, levels of ras-related proteins in rpAD HDFs were found to be sig-
nificantly decreased (Figure 33.A). 
 
Figure 33: Profile alterations of ras-related proteins. A) differential expression levels of 
ras-related proteins in subtype-specific HDFs (relative expression is represented as Z-
score). B) global proteome validation in frontal cortex samples for spAD (n=3), rpAD (n=3), 
DLB (n=3), rDLB (n=3), D-FTL (n=3), SVD (n=3), and controls (n=3), respectively. F12‒
F17: HDF pool-12 to 17. 
For most SWATH-MS-quantified ras-related proteins, there were no significant differ-
ences among the compared dementia subtypes. Highly significant differences were 
only observed for ras/rap GTPase-activating protein SynGAP (SYNGAP1), with a sig-
nificant increase observed in DFTL and SVD in comparison to other groups. Likewise, 
expression of ras-related protein Rab3A was found significantly reduced in rpAD in 
comparison to controls, DFTL, rDLB, and DLB. Expression of Rab3C was observed to 
be significantly decreased in spAD, rpAD, and SVD, compared to Con, but no signifi-




rpAD exhibited a proteomic profile of ras-related proteins very similar to that of spAD 
(Figure 33. B). 
3.4.3.4 Cytoskeletal proteins 
Several cytoskeleton-associated proteins were quantified with MS/MS quantification 
in HDFs and SWATH-MS global proteome. Levels of tubulin subunits were observed 
to be significantly reduced in rpAD HDFs compared to other groups. A significant de-
crease was also seen for the levels of the neurofilament subunits, actin and actin-
binding proteins in rpAD HDFs levels. Conversely, significantly higher levels of micro-
tubule-associated proteins (MAP1A, MAP1B, and MAP2), flaming (FLNA), filaggrin 
(FLG) and plectin (PLEC) were observed in rpAD HDFs compared to sCJD-specific 
HDFs (Figure 34). Among the cytoskeletal proteins from global proteome data, ex-
pression of actin G (ACTG) was found to be significantly increased in rpAD compared 
to controls, whereas no significant differences were observed between the spAD and 
rpAD. ACTG expression was observed to be significantly decreased in SVD and DFTL 





Figure 34: Variations in cytoskeletal proteins in high-density fractions. The relative 
abundance of cytoskeletal proteins in HDFs detected using high-resolution MS/MS analysis 
is represented as Z-score. Significant lowering of cytoskeletal proteins was seen in rpAD-
specific HDFs. F12‒F17: HDF pool 12 to 17. 
Contactin 1 (CNTN1) expression was also found significantly higher in SVD and DFTL 
compared to rpAD, whereas no differences were seen in CNTN1 expression between 
rpAD and rDLB. Expression of tubulin alpha 1a (TBA1A) was observed to be signifi-
cantly higher in rpAD compared to other rapid dementia brain cortex samples, i.e. 
DFTL, SVD, and r-DLB. Likewise, expression of TBA4A was differentially higher in 
rpAD compared to Con, DLB, DFTL, and SVD. A highly significant decrease, in con-
trast, was observed in the rpAD expression of septin-B in comparison to that of SVD, 
DFTL, and DLB. Overall, the pattern of cytoskeletal proteins in global proteomics data 
was similar in spAD and rpAD, but the other rapidly progressive dementia samples 





Figure 35: Expression differences of cytoskeletal-(associated) proteins as deter-
mined by the SWATH-MS. Heatmaps represent the relative protein expression indicated 
as Z-scores for spAD (n=3), rpAD (n=3), DLB (n=3), rDLB (n=3), D-FTL (n=3), SVD (n=3), 
and controls (n=3). 
3.4.3.5 Subtype-specific changes in chaperones 
Differential regulations were also observed in subtype-specific chaperone levels in the 
HDFs. In the rpAD HDFs, a significant increase was observed in MS-quantified chap-
erones, compared to controls, AD and sCJD subtypes (Figure 36.A). In the global pro-
teomic SWATH-MS dataset, most of the detected chaperones did not show statistically 
significant intergroup differences, except for the 60 kD heat shock protein (CH60), heat 
shock protein 70 kD (HSP70) and heat shock cognate 71 kD protein (HSP7C). For the 
CH60, a significant decrease was observed in comparison to that of spAD and con-






Figure 36: Differential chaperone expression levels in HDFs. A) Heatmap represents 
the relative levels of chaperones in high-density fractions (indicated as Z-score). Significant 
increase in the HDF expressions of chaperones was seen in rpAD-HDFs B) Baseline rela-
tive expression levels of chaperones (expression estimated by SWATH-MS) for spAD 
(n=3), rpAD (n=3), DLB (n=3), rDLB (n=3), D-FTL (n=3), SVD (n=3), and controls (n=3). 
F12 to F17: HDF pool 12 to 17.  
A statistically significant increase was seen in the levels of HSP72 in rpAD in compar-
ison to the other groups in the proteomic dataset. Whereas, the rpAD expression of 
HSP7C was also observed to be lowered, in comparison to other groups (Figure 36.B). 
3.5 Identification of binding interactors for high-density prion oligo-
mers (HDPs) 
A high throughput co-immunoprecipitation assay was carried out, using an anti-prion 




oligomers, and to establish whether HDP oligomers interfere with the proteins from 
previously described protein groups. Co-IP was carried out from the same protein 
pools of high-density fractions, as used for the high-resolution MS/MS analysis of 
HDFs. The experimental setup is described below (Figure 37.A). 
 
Figure 37: Disease subtype-specific binding interactors of high-density prion oligo-
mers. A) Illustration showing the experimental setup for performance of t the co-immuno-
precipitation. B) Numerical Venn-diagram showing the overlap of subtype-specific HDP in-
teractors. IP-F-Con: high-density PrP (HDP) interactors in control HDFs pools from 12-17 
(collectively), IP-F-spAD: HDP interactors in spAD HDFs pools from 12-17, IP-F-rpAD: HDP 
interactors in rpAD HDFs pools from 12-17, IP-F-MM1: HDP interactors in sCJD-MM1 
HDFs pools from 12-17, IP-F-VV2: HDP interactors in sCJD-VV2 HDFs pools from 12-
17IP-F-MM2: HDP interactors in sCJD-MM2 HDFs pools from 12-17.  
3.5.1 Rapidly progressive Alzheimer’s disease-specific high-density PrP in-
teractors 
Interestingly, the HDP interactomes of controls and spAD subtypes had no interactors 
in common with the rpAD-specific interactors of HDPs. However, some of the HDP 
interactors from rpAD HDFs were also commonly found as the interactors of HDP 
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F12 to F17: HDF pool-12 to 17, Ce: centrosome, Sy: Synapse, Sr: sarcoplasmic reticulum, 
C: Cytoplasm, Ck: cytoskeleton, Nu: Nucleus, S: Secreted, Cm: Cell membrane, Sl: Sar-
colemma, Ly: Lysosomes, Mc: Mitochondrion, Syo: Synaptosome, Cj: Cell junction, C V: 
cytoplasmic vesicles, Ga: Golgi apparatus, Pm: phagosome membrane, Px: peroxisome, 
Em: Endosome membrane, Cp: Cell projection, Gc: growth cone, Ms: Melanosome, Er: 
Endoplasmic reticulum and La: Lipid-anchor. The localization of proteins and accession 
number are assigned as in ExPASy protein database and Uniprot database, respectively. 
Three interactors, namely mammalian ependymin-related protein 1 (EPDR1), CaMKII 
subunit beta (CAMK2B) and CaMKII subunit delta (CAMK2D) were commonly found 
interacting with HDPs in IP-F-rpAD and sCJD fractions i.e. IP-F-MM1, IP-F-MM2 and 
IP-F-VV2. IP-F-VV2 and IP-rpAD also shared another common interactor namely 
GTP-binding protein Di-Ras2 (DIRA2) (Figure 37.B, Table 13). 
Though the spectrum of rpAD-specific HDP-interactors was not broad, the interactors 
identified belonged to diverse cellular activities. In total, six interactors could be iden-




sCJD subtype-specific fractions. Calcium/calmodulin-dependent protein kinase type II 
(CaMKII) has been previously reported to be relevant in Alzheimer’s disease, however, 
the disease relevance of ependymin-related protein 1, GTP-binding protein Di-Ras2 
and GAS2-like protein 2 have not been reported so far, in curated databases (Table 
13). Subtype unique HDP interactors and HDP interactors commonly occurring in sam-
ples from spAD and sCJD subtypes are discussed in the supplementary data section 
6.1, Table 19, Table 20 and Table 21. 
3.5.2 The physiological coherence of subtype-specific high-density PrP bind-
ing proteins 
The pathway enrichment analysis of HDP interactors resulted in an interesting out-
come. No overlap could be observed in PrP interactors from spAD and rpAD HDFs. 
On the contrary, the physiological pathways shown for the rpAD also appeared to be 
affected in sCJD subtypes, suggesting a similar involvement of HDPs in the patho-
physiology of the two diseases (Figure 38). 
 
Figure 38: Enrichment analysis of subtype-specific HDP interactors, based on Reac-
tome-pathway database. The graphical presentation exhibits adjusted p-values for corre-




3.6 Growth arrest-specific 2-like 2 (G2L2) and potential interaction 
to HDPs 
Out of the candidates identified as HDP interactors in rpAD, growth arrest-specific 2-
like 2 (G2L2) was selected for further functional verification. G2L2 was selected, be-
cause it is a unique interactor to rpAD-specific HDPs and for its essential role in the 
cytoskeletal integrity (actin-microtubule assemblage), as the prior MS/MS analysis of 
HDFs had also indicated differential cytoskeletal anomalies among the disease sub-
types. G2L2 is reported to play a role in the co-alignment of actin filaments and micro-
tubules bundles, by cross-linking the two together. This cross-linking is assisted by the 
end-binding protein-1 (EB-1) in the actin filaments (Stroud et al., 2014). To study G2L2 
comprehensively, the proteins associated with the physiology of G2L2 including EB-
1, tubulin and actin were also tested in the study. 
3.6.1 Expression of G2L2 and associated proteins in Alzheimer’s subtypes 
Immunoblotting-based expression analysis of brain frontal cortex protein isolates 
showed no significant differences in the expression of G2L2 between the AD-subtypes 
and Con. Likewise, no significant differences in expression could be seen for EB-1, 
tubulin-α, and actin-β (Figure 39). 
 
Figure 39: Expression regulation of G2L2 and associated proteins. A) Immunoblots 
showing the expression levels of G2L2, EB-1, tubulin-α, and actin-β. B-E) Densitometric 
analysis for G2L2, EB-1, tubulin, and actin, carried out using immunoblots for spAD (n=7), 
rpAD (n=7) and controls (n=6), in three independent experiments. No significant expression 
differences could be found for the G2L2 and associated proteins. Statistical significance 
was calculated with one-way ANOVA followed by Tukey post-hoc test to compare all pairs 




3.6.2 Colocalization of G2L2 and associated proteins in brain frontal cortex 
After not having been able to identify differences in expression, we investigated the 
colocalization patterns of G2L2 with PrP and EB-1, tubulin-α, and actin-β in AD-sub-
types and controls. Tubulin-α and actin-β colocalization was also visualized for as-
sessment of the functional integrity the cytoskeletal system. 
3.6.2.1 Neuronal co-localization of G2L2 and PrP 
By comparing the colocalization patterns of G2L2 and PrP, a certain subtype-specific 
trend was apparent. Immuno-histological observations were made from the grey mat-
ter areas of the frontal cortices from the controls and AD subtypes. The highest level 
of colocalization between PrPC and G2L2 was observed in frontal cortex tissues of 
rpAD (Figure 40.p) followed by spAD (Figure 40. j) cortical sections. 
 
Figure 40: Characteristic colocalization of G2L2 and PrP in rpAD, spAD and control 
brains. Brain frontal cortex sections of rpAD (n=3), spAD (n=3) and controls (n=3) were 
stained using anti-G2L2 and anti-PrP (SAF70) antibodies. Scale bars = 50µm. Colocaliza-
tion frequency plots (panels e, k, q) and correlation plots (panel f, l, r) were prepared using 
intensity correlation analysis plug-in in ImageJ. 
Intensity correlation analysis (ICA) of channel intensities was performed for PrPC and 
G2L2 channels to quantitatively define the colocalization. Colocalization frequency 
plots (shown in Figure 40, e, k, and q) and the channel intensity correlation plots (Fig-
ure 40, f, l and r) also represent the highest G2L2-PrPC colocalization in rpAD followed 
by spAD and controls, respectively. Threshold Mander’s coefficient (tM) and Pearson 




value of tM1 shows the overlap of G2L2 channel pixels to PrPC channel pixels, which 
is significantly higher in rpAD than in spAD. On the other hand, tM2 (representing the 
overlap of PrPC channel pixels to G2L2 channel pixels) is also significantly higher in 
rpAD than in spAD. High rP-values show that there is a strong correlation between the 
PrP and G2L2 in colocalization areas (Figure 41). 
 
Figure 41: Correlation coefficients for colocalization of G2L2 and PrP in frontal cor-
tex of rpAD, spAD and control frontal cortex tissues. Brain frontal cortex sections of 
rpAD (n=3), spAD (n=3) and controls (n=3) were stained using anti-G2L2 and anti-PrP 
(SAF70) antibodies. Threshold correlation coefficient values were calculated using intensity 
correlation plugin in ImageJ from micrographs scanned at 630x magnification. Statistical 
significance was calculated using one-way ANOVA. Tukey post-hoc test was used to cal-
culate the intergroup statistical differences. **p < 0.005; ***p < 0.001 
3.6.2.2 G2L2 and EB-1 binding 
We hypothesized that the interaction of HDP oligomers with G2L2 (shown in Figure 
40) may interfere with the interaction of G2L2 and EB-1, necessary for the downstream 

























Figure 42: Characteristic colocalization of G2L2 and EB-1 in the frontal cortex of AD 
and control brains. Brain frontal cortex sections of rpAD (n=3), spAD (n=3) and controls 
(n=3) were stained using anti-G2L2 and anti-EB-1 antibodies. Scale bars = 50 µm. Colo-
calization frequency plots (shown in e, k, and q) and correlation plots (f, l, r) were prepared 
using intensity correlation analysis plug-in in ImageJ. 
A significant decrease in G2L2 and EB-1 colocalization was observed in the frontal 
cortex brain tissues of rpAD compared to spAD cortical sections and controls. Intensity 
correlation analysis (ICA) of channel intensities was performed for EB-1 and G2L2 
channels to quantitatively define the colocalization extent. Colocalization frequency 
plots (shown in Figure 42 e, k, and q) and the channel intensity correlation plots (Figure 
42 f, l and r) also show the colocalization to be minimum in rpAD followed by the higher 
overlap in spAD and maximum in control frontal cortex tissues. Significantly decreased 
G2L2 (tM1) and tM2 (EB-1) values in rpAD in comparison with those of spAD represent 
the lower degree of colocalization in rpAD. A strong correlation between the EB-1 and 






Figure 43: Correlation coefficients for colocalization of G2L2and EB-1 in frontal cor-
tex of rpAD, spAD, and controls. Brain frontal cortex sections of rpAD (n=3), spAD (n=3) 
and controls (n=3), were stained using anti-G2L2 and anti-EB -1 antibodies. Threshold cor-
relation coefficient values were calculated using the intensity correlation plugin in ImageJ 
from micrographs scanned at 630x magnification. Statistical significance was calculated 
using one-way ANOVA. Tukey post-hoc test was used to calculate the intergroup statistical 
differences. *p < 0.05 
3.6.2.3 G2L2/tubulin-α colocalization 
To study the hypothesized disruption in G2L2 and tubulin-α integrity under the influ-
ence of HDPs, we studied the colocalization of G2L2 and tubulin-α in frontal cortex 
tissues of AD subtypes. 
 
Figure 44: G2L2 and tubulin-α localization in the frontal cortex of rpAD and spAD 
brains. Brain frontal cortex sections of rpAD (n=3) and spAD (n=3) were stained using anti-
G2L2 and anti-tubulin-α antibodies. Scale bars in panels A.a -A.d and panels B.a -B.d 
measure 50 µm and 10 µm in Ae and Be. ICA plots (panels A.f-g and B.f-g), colocalization 
frequency plots (panels A.i and B.i) and correlation plots (panel A.h and B.h) were prepared 
using intensity correlation analysis plug-in in ImageJ.  
Scanning laser micrographs showed a low degree of colocalization for G2L2 and tu-


























frequency plots (Figure 42 e, k, and q) and the channel intensity correlation plots (Fig-
ure 44, A.h and Figure 44, B.h) represent the low level of colocalization in both rpAD 
and spAD. Values of tM1 (G2L2) and tM2 (tubulin-α) did not show any significant dif-
ferences (Figure 45).  
 
Figure 45: Correlation coefficients for colocalization of G2L2 and tubulin-α in the 
frontal cortex of rpAD and spAD. Frontal cortex section from rpAD (n=3) and spAD (n=3) 
were stained with anti-G2L2 and anti-tubulin antibodies. Threshold coefficient values were 
calculated using the intensity correlation plugin in ImageJ from micrographs scanned at 
630x magnification. Statistical significance was calculated using one-way ANOVA.  
3.6.2.4 G2L2/actin-β colocalization 
We could not establish any significant difference in the colocalization between the ac-
tin and G2L2 in frontal cortex gray matter areas of spAD and rpAD brain tissues. Dis-
tant distribution of channel-intensities in the correlation plots in (Figure 46 A, panel h 
and Figure 46 B, panel h) represent the non-existent colocalization between G2L2 and 
actin. Likewise, the colocalization-frequency calculations showed a very low extent of 
colocalization in the two channels only in spAD sections (Figure 46 A, panel i and 

























Figure 46: G2L2 and actin-β distribution in the frontal cortex of rpAD and spAD 
brains. Brain frontal cortex sections of rpAD (n=3) and spAD (n=3), were stained using 
anti-G2L2 and anti-actin-β antibodies. Scale bars in panels A.a-A.d and B.a-Bd measure 
50 µm and 10 µm in panel A.e and B.e. ICA plots (panels A.f-g and B.f-g), colocalization 
frequency plots (shown in panels A.i and B.i) and correlation plots (panel A.h and B.h) were 
prepared using Intensity correlation analysis plug-in in ImageJ. 
3.6.2.5 Actin-β/tubulin-α integration 
Probable disruptions in actin-tubulin co-alignment were also studied using confocal 
laser scanning microscopy. Frontal cortex sections (5 µm thick) were stained for tubu-
lin-α and actin-β and were scanned for the confocal z-sections, and later used for the 
construction of three-dimensional images.  
 
Figure 47: Actin-β and tubulin-α colocalization in the frontal cortex of AD-subtypes. 
Brain frontal cortex sections of rpAD (n=3) and spAD (n=3), were stained using anti-tubulin-
α and anti-actin-β antibodies. A.e and B.e represent region of interests at higher magnifi-
cation. A.h and B.h represent three-dimensional reconstruct from the z-sections. Scale bars 
in panels A.a-A.d and B.a-B.d correspond to 50 µm and 25 µm in panel A.e and B.e. Col-
ocalization frequency plots (panels A.f and B.f) and correlation plots (panel A.g and B.g) 




A more pronounced actin-tubulin colocalization was observed in the spAD samples in 
comparison to rpAD (Figure 47 A, panel e and Figure 47 B, panel e) shown also by 
the colocalization-frequency plots (Figure 47 A, panel f and Figure 47 B, panel f). Like-
wise, in correlation plots calculated for the actin and tubulin channels, we could also 
see significantly higher overlap between the channel intensities (Figure 47 A, panel g 
and Figure 47 B, panel g). Three-dimensional reconstructs from the z-sections show 
longer stretches of filaments with actin-tubulin colocalization in spAD compared to 
rpAD with higher actin and tubulin channel overlap (Figure 47 A, panel h and Figure 






Alzheimer’s disease is the most commonly occurring dementia of the elderly, consti-
tuting up to 75% of all dementias either exhibited as an independent entity or occurring 
as comorbidity disease. Typically, Alzheimer’s disease is a slowly progressive disease 
with either spontaneous development of characteristic symptoms in sporadic cases, 
or due to an associated mutation in presenilin 1, 2 and APP. Over the past few dec-
ades, some atypical AD cases have been reported, with a rapid cognitive decline of 
>6 MMSE points a year and a shorter post-diagnostic survival, spanning ~4 years. The 
aim of the current study was to characterize the mechanisms leading to progression 
rate variations in AD. The study was based on brain frontal cortices from rpAD and 
spAD, sCJD subtypes (MM1, MM2 and VV2), DLB, rDLB, SVD, and DFTL. Frontal 
cortex tissues were selected to carry out the experimentation, as the cortical pathology 
in neurodegenerative disease marks the end stages of the disease (Braak & Braak, 
1991). The study focuses on many aspects linked to Alzheimer’s disease including 
basic pathological alterations, changes in the kinome involved in the neurodegenera-
tive diseases and primarily the metabolism of prion protein and biochemical and phys-
iological characterization of the rpAD-unique PrP-oligomers. 
4.1 Amyloid plaques and Tau tangles 
We were able to identify slight differences in the development of amyloid plaques. The 
amyloid plaques in the rpAD frontal cortex were observed at higher frequencies but 
they were rather small in rpAD in comparison to other subtypes. However, non-signif-
icant differences were seen for Tau tangle frequency and size in the rpAD when com-
pared to spAD cases. Biochemically, we could not identify any subtype-specific differ-
ences in the expression of Aβ and Tau levels, nor in the phosphorylation of Tau. Con-
formation variants of Aβ oligomers have been extensively studied by many groups. 
Human brain derived Aβ has been used in some studies to seed synthetic Aβ and 
resultant differential species have been further examined for structural differences (Lu 
et al., 2013; Qiang, Yau, Lu, Collinge, & Tycko, 2017). Likewise, work from Cohen et 
al. (2016) has exhibited the structural variation in the Aβ species persisting between 
spAD and rpAD. Biophysically divergent species of Aβ have also been described by 
Rasmussen et al., with the spAD and FAD cases. In the study, classification of Aβ 




oligophenes (LCOs). An association between different Aβ-conformational variants and 
disease subtypes including spAD and FAD with mutations including APP V717I, 
PSEN1 A431E, PSEN1 F105L, PSEN1 E280A cases, was observed in the study. Sur-
prisingly, age-dependent variation in Aβ-conformation was also noted in a mouse 
model, (Rasmussen et al., 2017). However, the mechanistic details of these discrep-
ancies in Aβ conformation remain unclear.  
The increase in the plaque and tangle frequencies in our cohort can be inferred as the 
higher degree of failure in the control mechanisms checking the oligomers in brain 
interstices. Failure in the conversion of soluble oligomers to insoluble fibrils/plaques 
may be the cause of a higher number of smaller sized plaques and tangles. Differential 
signal transduction and prion protein metabolism were investigated further to reveal 
the mechanism leading to amyloid profiles. 
4.2 Differential signal transduction 
Differential signal transduction has been associated with neurodegenerative disease. 
Specifically AD has diverse associative variations in signaling events, including Wnt 
signaling (Inestrosa & Varela-Nallar, 2014), MAPK signaling (Kim & Choi, 2015), p38 
MAPK signaling (Munoz & Ammit, 2010), NFkB signaling (Li, Long, He, Belshaw, & 
Scott, 2015), AMPK signaling (Godoy, Rios, Zolezzi, Braidy, & Inestrosa, 2014) and 
Fyn signaling (Um & Strittmatter, 2013). Furthermore, a battery of kinases, including 
Fyn, AKT, PKA, CaMKII, Cdk5, MAPK and MARK, is responsible for Tau phosphory-
lation (Querfurth & LaFerla, 2010). In the current study, we aimed to differentiate spe-
cific signal transduction pathways involved in the pathological events and most im-
portantly progression rate differences. Kinases including AKT, ERK, p38, NFkB, 
GSK3-β, MYLK, MP2K4, KPYM, PI424, KPC, CaMKII, MK01, and SRC, were studied 
for the total expression and expression of phosphorylated forms. Only CaMKII subunit 
B was observed to be up-regulated in the spAD cortex compared to rpAD and Con. 
CaMKII is known for its Tau-phosphorylation activity (Ghosh & Giese, 2015). Up-reg-
ulation of CaMKII-B can be considered responsible for the slightly higher (though non-
significant) phosphorylation of Tau in spAD. Interestingly, the differences in kinase 
expression profiles between the Alzheimer’s subtype and the control cohort were also 
not significant, suggesting that it then may well be associated with changes originating 




4.3 Prion protein metabolism (differential glycoforms and distribu-
tion) 
In recent years, PrPC has been shown to interact with amyloid-β species (Dohler et 
al., 2014). Cell surface PrPC is reported to act as a receptor for oligomers resulting in 
neurotoxicity (Zhou & Liu, 2013). On the other hand, shed-PrP (sPrP) promotes the 
fibrilization of extracellular Aβ oligomers (Altmeppen et al., 2012). Moreover, earlier 
studies from Jiri Safar’s group have established that there is a distinct increase in the 
low molecular weight species of Aβ oligomers in rpAD cases in comparison to spAD 
(Cohen et al., 2015). We hypothesized that the differences in the Aβ oligomer-induced 
neurotoxicity is a contributing factor to progression rate variations in AD subtypes and 
the cause of this increased population of low molecular weight oligomers reflects al-
terations in PrP metabolism. Expression analysis revealed a significant decrease in 
the di-glycosylated isoform of PrP (DG-PrP), although no significant differences were 
observed in the total PrP. Variations in the DG-PrP have already been reported, in the 
context of prion strain variations (Aguzzi, Heikenwalder, & Polymenidou, 2007; Khalili-
Shirazi et al., 2005; Neuendorf et al., 2004), but the mechanism leading to such differ-
ences the glycosylation patterns have not been understood. Some studies show the 
data with a decrease in extracellular shedding of PrPC as a result of a decrease in DG-
PrP (Linsenmeier et al., 2018). Therefore, we checked the distribution of extracellular 
PrP in our cohort and established a significant decrease in the shed-PrP. Interestingly, 
we found a significant decrease in the extracellular PrP. We also saw a higher nuclear 
accumulation of PrP (Zafar, Shafiq, et al., 2017). A previous study from Say et al., 
(2007) suggests that the perinuclear presence of PrP might arise due to the recycling 
of plasma membrane to the nucleus (Say & Hooper, 2007). However, nuclear colocal-
ization of PrP and histone has been verified in a study by Strom et al., (2011). Prion 
protein has also been reported to localize in the nucleus under genotoxic conditions 
acting as a strong activator of DNA repair via the central base excision repair enzyme, 
the AP endonuclease. (Bravard et al., 2015). From the above-mentioned debate and 
corresponding results from our study, we think that the disrupted localization of PrP in 
the brain tissue interferes with the amyloid sequestering, hence a higher number of 
toxic lower molecular weight oligomers are available in rpAD cases in comparison to 





Figure 48: Prion protein shedding in AD-subtypes. Shedding of prion protein is propor-
tional to the degree of glycosylation in PrP (Linsenmeier et al., 2018). Extracellular levels 
of prion protein have been found decreased in rpAD frontal cortices. Less extracellular PrP 
results in the decreased sequestering of Aβ oligomers, resulting in rapid spread in rpAD, 
hence a higher neurotoxicity. 
4.4 Subtype-specific PrPC interactors 
Prion protein has been actively studied for its binding interactors with the aim of un-
derstanding the underlying physiological aspects. Prion protein interacts with the lig-
ands belonging to three major molecular categories, namely metal ions, single molec-
ular interactors, and multimolecular complexes. The octapeptide region of surface 
PrPC is often reported to interact with divalent metal ions, particularly Cu2+ (Brown et 
al., 1997), Ni2+, Zn2+ and Fe2+ (Jackson et al., 2001) leading to conformational 
changes, in turn activating N-methyl-D-aspartic acid receptors (NMDA) (Singh, Das, 
Singh, & Mohan, 2010). The PrP-metal associations have also been discussed as a 
control mechanism of oxidative stress (Singh et al., 2010). Prion protein is also re-
ported to interact with other proteins and RNA molecules. Well-established-prion pro-




Fede et al., 2007; Richard et al., 2003; Satoh, Onoue, Arima, & Yamamura, 2005), 
cytoskeletal proteins, including synapsin 1b (Spielhaupter & Schätzl, 2001), glial cell 
fibrillary acidic protein (Dong et al., 2008), tubulin isoforms (Nieznanski, Nieznanska, 
Skowronek, Osiecka, & Stepkowski, 2005; Osiecka et al., 2009), microtubule-associ-
ated protein-MAPT (Wang et al., 2008), stress-inducible protein 1 (Ostapchenko et al., 
2013), Rab7a and lactate dehydrogenase (Zafar et al., 2014), RNA binding proteins, 
and some other proteins including growth factor receptor-bound protein 2, b-cell lym-
phoma 2 protein, nuclear factor erythroid 2-related factor 2, casein kinase 2 (Nieznan-
ski, 2010). 
In the current study, we have characterized subtype-specific PrP interactors in Alz-
heimer’s disease. Histone H2B2 and zinc alpha 2 glycoprotein (ZAG) have been iden-
tified as novel PrP interacting proteins from rapidly-progressive forms of the AD. One 
protein, myelin P2, was isolated as the sole binding partner to the PrP isoform in spAD 
samples. We also identified PrP interacting proteins for both subtypes of Alzheimer’s 
disease studied including transketolase, myelin basic protein, peroxiredoxin-1, and 
four and a half LIM domains protein 1. Interestingly, physiological relevance for the 
ZAG and histone H2B2 was established earlier, for the Alzheimer’s and PrP function. 
ZAG is a protein with multiple reported functions, including lipid mobilization, and ribo-
nuclease activity (Hassan, Waheed, Yadav, Singh, & Ahmad, 2008; Lei, Arany, Tyring, 
Brysk, & Brysk, 1998), and was previously reported for an increase in expression in 
serum of Alzheimer’s disease patients; but the physiological significance of increased 
expression has not been discussed (Shen et al., 2017). Histone interaction with the 
prion protein has been previously reported, with a suggestive role in transcriptional 
control (Rousset, Leturque, & Thenet, 2016; Strom et al., 2011). Among the interactors 
commonly present in AD-subtypes, peroxiredoxin-1 plays a protective role in cell redox 
stress (Kang et al., 1998). Four and a half LIM domains protein 1 is involved in cell 
morphogenesis (Sato K et al., 2016). Transketolase isoform functions as a phosphate-
adding enzyme acting over sugars and is important in mammalian glycolysis. Myelin 
basic protein has a role in myelination and brain development (Nye et al., 1995). 
Though functional outcomes of subtype-specific PrPC interactions have yet to be es-
tablished. We recognized that the differences in interactors might be a result of various 
types of PrP conformers. To this end, for the next phase of the study we focused on 




4.5 Prion protein oligomers in rpAD 
Multiple PrP conformers have been previously described in the association of trans-
missible spongiform diseases in animals and humans (Cracco et al., 2017; Imran & 
Mahmood, 2011; Kitamoto & Tateishi, 1994). In recent years, many studies have fo-
cused on the existence of soluble PrP oligomers of varying molecular weights, as the 
toxic mediators of disease (Cracco et al., 2017; Haass & Selkoe, 2007; Haldiman et 
al., 2013; C. Kim et al., 2011, 2012). However, AD has not previously been associated 
with variant PrP oligomer populations. In the current study, we examined density var-
iant PrP oligomers in AD frontal cortices. Frontal cortex tissues from sCJD were used 
as positive controls. We were able to identify unique assemblies of PrP associated 
specifically with the rpAD and sCJD in high-density fractions, suggesting an overlap 
of properties between the prion oligomers of rpAD and sCJD-subtypes. However, no 
similarities between the rpAD- and sCJD-specific PrP oligomers could be established 
in proteinase-K digestion assays or the seeding activity assay (via real-time quaking-
induced cyclic amplification). Presence of HDP oligomers in rpAD can specifically be 
indicative in two different domains; firstly, the loss of function with the PrP conformers 
resulting in their malfunction due to the inability to perform normal physiological func-
tions, secondly, gain of function with higher neurotoxicity directly induced by the PrP 
oligomers.  
4.6 Differentially distributed proteins in high-density fractions 
High-resolution MS/MS analysis of HDFs was carried out to study the subtype-specific 
protein expression. Differential mass spectrometric analysis when compared to base-
line global proteome (SWATH-MS based), highlighted rpAD-specific alterations in cer-
tain physiological domains, including ubiquitin, proteasomal subunits, ras-related pro-
teins, chaperones, and the cytoskeletal machinery, as well as a higher over-all prote-
opathic burden. 
4.6.1 Proteopathic proteins and protein degradation machinery 
High-density fractions of the sCJD subtypes showed the highest levels of proteopathic 
proteins followed by the rpAD HDFs, except for serpins. Serpin levels were signifi-
cantly higher in spAD compared to that of rpAD. The increased levels of proteopathic 




degradation machinery as well as an increase in molecular events that promote the 
polymerization of the proteopathic proteins; alterations in these physiological domains 
associated with rpAD and sCJD could also be observed in the HDF proteomic profiles. 
Experimentally, we observed a differential distribution of ubiquitin and proteasomal 
subunits. Levels of ubiquitin subunits were significantly reduced in rpAD fractions com-
pared to controls and spAD HDFs. Similar decreased expression levels were also ob-
served for sCJD HDFs. However, highest levels of proteasomal subunits were found 
in sCJD HDFs, in contrast to rpAD HDFs, where the HDF levels of proteasomal subu-
nits were found significantly decreased. The protein degradation machinery (pro-
teasomal subunits and ubiquitin isoforms) has already been discussed as the control 
mechanism for the removal of misfolded proteins (Checler and Vincent, 2002; Klaips, 
Jayaraj & Hartl, 2018). Synaptic aggregates of hyperphosphorylated Tau have also 
been associated with pathophysiological alterations of the ubiquitin-proteasome axis 
(Tai et al., 2012). The decrease in the proteasomal abundance in the rpAD-specific 
fractions is indicative of the relatively higher proteopathic burden in rpAD and the pres-
ence of rpAD unique PrP oligomers. We considered that the increase in sCJD pro-
teasomal subunits is related to the higher abundance of the proteopathic proteins. 
4.6.2 Ras-related proteins 
Rab-GTPases have been reported generally to take part in vesicle formation, vesicular 
transport in both endocytic, exocytic pathways and membrane trafficking (Bucci, 
Thomsen, Nicoziani, McCarthy, & van Deurs, 2000). However, unique subsidiary roles 
are assigned to specific ras-related proteins. Rab11 has been reported for its role in 
the expression control of potassium channels and Cav1.2 calcium channel (Best et 
al., 2011; Delisle et al., 2009). Ras-related protein Rab14, through its interaction with 
FAM116, modulates the subcellular distribution of ADAM10 in migrating cells (Linford 
et al., 2012). Involvement of Rab7a along with the PrP in the vesicular transport has 
been well characterized previously (Zafar et al., 2011). Rab21 has been shown to reg-
ulate integrin trafficking necessary for cytokinesis. In our study, levels of ras-related 
proteins were observed to be significantly higher in the HDFs from sCJD subtypes 
compared to AD subtypes and controls. Contrary to our expectation, the differential 
HDF levels of ras-related proteins point more towards variant pathological events in 
action in rpAD than those of sCJD. Increase in the sCJD-HDF levels can be an indi-




proteins are described to be associated with the vesicles, Golgi complex and ER in 
many studies (Plutner et al., 1990; Tisdale et al., 1992; Zafar et al., 2011; Banton et 
al., 2014; Zheng et al., 2015), we also argue that the higher HDF levels of ras-related 
proteins in sCJD subtypes correspond to higher levels of membrane vesicles as well 
as Golgi and ER fragments, due to higher neurodegenerative damage. 
4.6.3 Cytoskeletal components 
The cytoskeleton provides the basic framework of shape, support and, most im-
portantly, the transport process within the cell. Defects in cytoskeletal proteins lead to 
interrupted transport, and these are major features in neurodegenerative disorders 
(Brunden, Lee, Smith, Trojanowski, & Ballatore, 2017; Gartz Hanson et al., 2016; Mat-
amoros & Baas, 2016; Swanger, Mattheyses, Gentry, & Herskowitz, 2015). Decreased 
levels of tubulin in rpAD HDFs showed that cytoskeletal proteins are indicative of 
worse damage to the cytoskeletal system, as previously described (Richter-Lands-
berg, 2008; Tas & Kapitein, 2018). The decrease in the tubulin integrity marks the 
involvement of pathways linked predominantly to rpAD, compared to spAD. PrPC was 
reported previously to inhibit microtubule synthesis, through its direct interaction with 
tubulin (Nieznanski, Podlubnaya, & Nieznanska, 2006). Uniquely identified PrP oligo-
mers in rpAD can be associated with tubulin sequestration, resulting in a higher degree 
of microtubule damage. In our study, the decrease in the HDF levels of tubulin in rpAD 
is accompanied by higher levels of microtubule-associated proteins (MAP1 and 
MAP2). This increase of MAPs in HDFs is indicative of a higher degree of MAPs being 
sequestered in the tangles as described previously (Harada et al., 1994; Wang & Man-
delkow, 2016). MAPs sequestration also correlates with the loss of microtubule integ-
rity in the rpAD cortices. Higher levels of the cytoskeletal proteins in sCJD HDFs indi-
cate involvement of a different set of mechanisms. As the tubulin-PrP interaction has 
been previously investigated by many authors (Nieznanski et al., 2005, 2006; Osiecka 
et al., 2009; Scott-McKean et al., 2016), we argue that the higher levels of these cyto-
skeletal proteins (tubulin isoforms and microtubule-associated proteins) persists due 
to the high levels of HDPs. 
4.6.4 Chaperones  
Chaperones are involved in various cellular activities regarding the preservation of the 




preventing their misfolding in the first place, and/or by refolding the misfolded proteins. 
These general functions are shared by all the chaperones (Mayer, 2013; Radons, 
2016). Some specific activities include regulating parkin protein translocation to the 
mitochondria (Hasson et al., 2013), scaffolding for the spliceosomes and inflammatory 
signaling (Triantafilou, Triantafilou, & Dedrick, 2001; Yahata et al., 2000). In the pres-
ence of Aβ oligomers, chaperones molecules, including HSP70, clusterin (Clu) and α2-
macroglobin (α2M), are reported to accumulate in areas of oligomerization to prevent 
the spread of toxic oligomers (Mannini et al., 2012). Clu and α2M are also reported to 
inhibit the permeation of α-syn oligomers through the lipid membranes (Whiten et al., 
2018). The higher abundance of chaperones and associated proteins in rpAD HDFs 
indicates a possible positive feedback mechanism, to overcome the protein misfolding 
in rpAD high-density fractions. Most probably, the reduction in the chaperones in sCJD 
is suggestive of an increase in the protein misfolding extent in sCJD cases.  
4.7 Interactors of high-density prion (HDP) oligomers 
Diverse sets of prion protein interactors were identified from subtype-specific HDFs. A 
lower count of rpAD-specific HDP interactors was identified in comparison to that of 
sCJD. The sCJD tissues exhibit a wide spectrum of PrP/PrPSc oligomers, as previously 
reported (Cracco et al., 2017; C. Kim et al., 2011, 2012), compared to that of rpAD 
(Zafar, Shafiq, et al., 2017). This diversity of PrP/PrPSc oligomers in the sCJD pathol-
ogy can be a potential reason for the relatively diverse interactome in sCJD PrP oligo-
mers. There was no overlap of HDP interactors of rpAD to either spAD or control sam-
ples, assuring the subtype-specific occurrence of the PrP species in rpAD. Common 
interactors between the rpAD and sCJD datasets suggest the presence of common 
PrP oligomers. Proteins interacting with the prion oligomers in rpAD included cal-
cium/calmodulin-dependent protein kinase type II subunit beta and delta, mammalian 
ependymin-related protein 1, GTP-binding protein Di-Ras2, GAS2-like protein 2, and 
14-3-3 protein. All the interactors, except the GAS2-like protein, were part of the HDP 
interactomes in rpAD and those of sCJD. Calcium/calmodulin-dependent protein ki-
nase type II regulates Ca2+ mediated effects in neurons, it is also responsible for the 
actin reorganization in bundles leading to the development of the dendritic spines (Ste-
phenson et al., 2017). GTP-binding Di-Ras2 is a Ras GTPase and has been reported 
to be involved in cell morphogenesis. G2L2 has been reported to play a role in actin-




protein with many known interactions, and is involved in p53, protein kinase C, and 
AKT/mTOR signaling (Yang, Dicker, Chen, & El-Deiry, 2008). There is strong evidence 
in the literature for the involvement of 14-3-3 isoforms in various neurodegenerative 
diseases particularly prion dementias and Alzheimer’s disease, where 14-3-3 isoforms 
are found associated with PrPSc and Aβ plaques (Richard et al., 2003; Jun-ichi Satoh 
et al., 2005; Wang et al., 2008). Physiological outcomes of novel interactions of these 
proteins with the PrP oligomers have yet to be described. Thus, it may be justified to 
include G2L2 for further investigation, particularly for its role in actin-tubulin intercom-
munication. 
4.7.1 G2L2 and cytoskeletal machinery 
Actin and tubulin interlinking and communication is necessary for the proper function 
of the cellular transport system, morphogenesis, repair and many other related func-
tions in the cells. Actin-tubulin communication is mainly controlled by the spec-
traplakins, via their ability to bind actin and tubulin, as well as multiple spectrin and 
plakin domains (Suozzi, Wu, & Fuchs, 2012). Many diseases have been related to the 
malfunction of spectraplakins (Sonnenberg & Liem, 2007). Likewise, the family of 
growth arrest-specific (GAS) proteins and growth arrest-specific like (GASL) proteins 
have been connected to the same function of actin-tubulin linking, but the functional 
orchestration has not been well established (Goriounov, 2003). Other than cytoskele-
tal maintenance, GAS proteins also play a role in apoptosis and inhibition of cell divi-
sion (Brancolini, Benedetti, & Schneider, 1995; Brancolini & Schneider, 1994). Sur-
prisingly, a mutation in the G2L2 protein is reported to enhance the chances of Alz-
heimer development (Jian et al., 2016). A comprehensive experimental account on the 
GAS and GASL proteins was provided by Stroud and coworkers (2014), proposing a 
model where growth-specific like 1 (G2L1) and growth-specific like 2 (G2L2) are sug-
gested to control microtubular stability via attachment to end-binding protein-1 (EB-1). 
The interaction of the G2L2 and EB-1 to the tubulin is also reported to account for the 
stability of the microtubules (Stroud et al., 2014). 
In our study, we described a subtype-specific colocalization of PrP oligomers to G2L2 
in rapidly progressive Alzheimer’s disease. Correspondingly, we found a decrease in 




rpAD possess a tendency to recruit and bind G2L2. This HDP-G2L2 interaction is neg-
atively correlated to G2L2 and EB-1 binding.  
Hence, the disturbance in the G2L2/EB-1/tubulin systems leads to a malfunction in 
actin-assisted microtubule growth in the neurons. The shortening in the actin-tubulin 
colocalization fibers specifically noted in frontal cortices of rpAD patients can also be 
an outcome of the disturbance of G2L2/EB-1/tubulin. A putative mechanism of HDP 
oligomers interacting with the cytoskeletal system is shown in Figure 49. 
 
Figure 49: Recruitment of G2L2 to the high-density prion-oligomers. The recruitment 
of G2L2 towards the HDPs results in the loss of its binding to EB-1, affecting the actin-
guided microtubule (MT) integrity. 
Considering the extreme size of neurons, there is need of a robust transport system 
in the neuron to build up a connection between the cell body and neural processes, 
for various types of neuronal cargo including organelles, vesicles, cell signaling mole-
cules, RNA molecules, neurotransmitter receptors, and adhesion molecules (Hi-
rokawa, Niwa, & Tanaka, 2010; Maday, Twelvetrees, Moughamian, & Holzbaur, 
2014). The actin-guided MT growth also imparts a critical role to the structural stability 
of neurons including kinesin-based axon differentiation/polarization (Hirokawa et al., 




(Dent, Gupton, & Gertler, 2011; Prokop, 2013), and finally the morphodynamics of 
dendritic spines (Hirokawa et al., 2010; Hoogenraad & Bradke, 2009; Maday et al., 
2014). With any malfunctioning in the MT system, neurons suffer from a variety of 
degenerative events. 
4.8 Conclusion 
Results of our study have helped in defining multiple pathological layers that contribute 
to the variation of progression rates in Alzheimer’s disease. Based on our results, we 
can state that the dysregulation of PrPC glycosylation and extracellular shedding leads 
to a reduction in Aβ sequestering, a phenomenon keeping check on the extension of 
Aβ spread. The binding of PrP to ZAG in rpAD (as indicated by interactomics) also 
indicates the number of PrP molecules available for Aβ sequestering. Likewise, his-
tone H2B2 and PrP interaction and nuclear localization of PrP point towards the patho-
logical variations in PrP trafficking in rpAD. On the other hand, the presence of PrP 
oligomers and higher levels of high-density proteopathic proteins in rpAD compared 
to spAD, indicate landmark changes in protein degradation metabolism in neurons. 
Proteomic signature of high-density fractions obtained in velocity gradient centrifuga-
tion shows a higher degree of cytoskeletal damage associated with rpAD, together 
with a differential metabolism of ras-related proteins. Cytoskeletal damage was also 
highlighted by the rpAD-specific interaction of G2L2 with PrP oligomers (found in the 
interactome of HDFs). Finally, confocal laser scanning microscopy did not exclude the 
possibility that the interaction of HDPs with G2L2 results in the loss of G2L2 attach-
ment to EB-1. This loss of G2L2 and EB-1 may interfere with actin-guided microtubular 
e growth, resulting in neuronal growth abnormalities specifically associated with rpAD. 
The outcomes of the study are summarized in the overview (Figure 50). HDP interac-






Figure 50: Overview of pathophysiology in rpAD resulting from our study. Rapid pro-
gression rate in the rpAD cases can be attributed to multiple homeostatic events. Changes 
in prion protein shedding, cellular distribution and presumably the occupancy by ZAG in 
extracellular space results in decreased Aβ-sequestration, hence increasing the extent of 
neurotoxicity. Conformational changes in prion protein result in the oligomerization of PrP 
in rpAD cases, resulting oligomers pose the threat of neurotoxicity by interfering with the 
cytoskeletal machinery of neurons and promoting the process of neurodegeneration.  





Alzheimer’s disease is the most commonly occurring dementia of the elderly, compris-
ing up to 75% of all the neurodegenerative disorders. Alzheimer’s disease (AD) typi-
cally exhibits a slow progression rate, resulting in an average disease span of eight 
years. Classically, AD exists predominantly as two subtypes, the first group are cases 
with spontaneous onset, namely sporadic cases; whereas the second group, the fa-
milial Alzheimer’s disease (FAD), result due to mutations in presenilin 1, 2 and amyloid 
precursor protein (APP) genes. Over the past few decades, some atypical cases have 
been reported with a higher degree of pathological severity and rapid progression 
rates, i.e. with a decline of >6 MMSE points per year and a shorter post-diagnostic 
time (average of four years). 
The present study was undertaken to identify and characterize the mechanisms in-
volved in the progression rate variations in Alzheimer’s disease subtypes, using hu-
man frontal cerebral cortex samples from rapidly progressive AD (rpAD), sporadic 
(spAD), sporadic Creutzfeldt Jakob disease (sCJD), dementia with Lewy bodies with 
typical (DLB) and rapid progression (rDLB), rapid progressive cases with vascular de-
mentia (SVD) and dementia with frontotemporal lobar degeneration (DFTL). We have 
focused on multiple aspects associated with Alzheimer’s disease including basic 
pathological alterations, signal transduction pathways involved in the neurodegenera-
tive diseases, the metabolism of prion protein and biochemical and physiological char-
acterization of the rpAD-unique PrP-oligomers. 
Microscopic examination of pathological hallmarks revealed a decrease in amyloid 
plaque diameters, with a significantly higher frequency in cortices of rpAD patients 
compared to spAD. However, no significant differences were recognized in Tau tan-
gles in the AD subtype. We could not identify any significant differences in amyloid-β 
and Tau/p-Tau expressions in rpAD- and spAD-subtypes. 
Signal transduction pathways were assessed by expression analyses of a battery of 
kinases (and active forms) using immunoblot analysis and SWATH-MS-based quanti-
fication, and a slight increase in the CaMKII subunit gamma was observed in spAD in 
comparison to both controls and rapidly progressive cases of Alzheimer’s disease. 
Due to the involvement of prion protein in Aβ oligomer sequestering, we focused on 




decrease was noted in the di-glycosylated isoform of prion protein (DG-PrP) in rapid 
progressive AD cases, along with a decrease in the extracellular PrP levels. The re-
duction in the levels of both DG-PrP and extracellular PrP can be linked to the disturb-
ance in the amyloid-sequestering activity of prion protein and a consequent higher 
load of free toxic oligomers. A higher PrP-nuclear localization was also observed in 
rpAD frontal cortex tissues that can be associated with a higher genotoxicity. In addi-
tion, we were able to observe subtype-specific differences among PrP interactomes, 
with histone-2 B2 and ZAG specifically interacting with prion protein in rpAD frontal 
cortices, suggesting the presence of differential prion variants in Alzheimer subtypes.  
High-density variants of prion proteins (HDP) were uniquely observed in the rpAD 
frontal cortices. No PK-resistance and PrP-seeding activity could be observed from 
the identified HDPs. We could identify a rpAD-specific differential higher load of pro-
teopathic proteins, disturbances in the protein degradation machinery, cytoskeletal 
disfigurations, relative abundance of chaperones and differential metabolism of Ras-
related proteins (utilizing high-resolution mass spectrometry analysis of high-density 
fractions and SWATH-MS-based global proteomics). 
From the co-immunoprecipitation of high-density prion oligomers, we identified a 
rpAD-unique interactor, GAS2-like protein 2 (G2L2), together with the interactors com-
monly found among rpAD and sCJD high-density prion interactors, including cal-
cium/calmodulin-dependent protein kinase type II subunits beta and delta, mammalian 
ependymin-related protein 1, GTP-binding protein Di-Ras2 and 14-3-3 protein sigma. 
Due to involvement in actin-tubulin dynamics, and its unique interaction with rpAD 
high-density prion oligomers, GAS2-like protein 2 was further studied along with as-
sociated proteins. The G2L2 serves as a linker protein between the tubulin bundles 
and actin filaments to stabilize the microtubules via attachment to end binding protein-
1. A significantly more pronounced colocalization of G2L2 and PrP was seen in the 
frontal cortex tissues of rapidly progressive AD cases, with an associated decrease in 
the colocalization of G2L2 and end binding protein-1 (EB-1). A decrease in the actin-
β and tubulin-α co-localization was also noted in frontal cortex tissues of AD cases 
with rapid progression. 
Based on the results, we confirm that prion protein metabolism plays an important role 




leads to impairment of oligomer sequestration. Formation of PrP oligomers and their 
downstream intervention with cell signaling and cytoskeletal organization promotes 
the faster progression in rapidly progressive Alzheimer’ disease cases. Furthermore, 
the interaction of G2L2 with PrP oligomers targets the actin-tubulin stability and actin-








Table 14: Patient details of non-demented controls, Alzheimer’s disease and demen-
tia with Lewy bodies cohorts. 









1 rpAD1 Male 70 <4 VI/C 11:30 
2 rpAD2 Male 76 <4 VI/C 6:30 
3 rpAD3 Female 76 <4 VI/C 18:00 
4 rpAD4 Female 77 <4 IV/A 12:00 
5 rpAD5 Male 78 <4 V/C 3:30 
6 rpAD6 Female 79 <4 V 5:30 
7 rpAD7 Female 81 <4 III/B 6:00 
8 rpAD8 Male 83 <4 VI/C 5:30 
9 rpAD9 Male 83 <4 V/C 8:20 
10 spAD1 Female 56 >4 V/C 7:00 
11 spAD2 Male 64 >4 II/A 6:00 
12 spAD3 Female 67 >4 III/C 6:10 
13 spAD4 Male 69 >4 III/0 13:10 
14 spAD5 Female 71 >4 III/0 7:15 
15 spAD6 Female 72 >4 V/C 9:30 
16 spAD7 Female 75 >4 V/C 4:15 
17 spAD8 Male 78 >4 V/C 9:30 
18 spAD9 Female 82 >4 VI/B 1:45 
19 spAD10 Male 83 >4 III/0 7:25 
20 spAD11 Male 87 >4 V/C 7:05 
21 spAD12 Female 90 >4 IV/A 9:55 
22 spAD13 Female 93 >4 V/C 3:00 
23 DLB1 Female  71 >4 II 5:03 
24 DLB2 Female  87 >4 - 5:00 
25 DLB3 Male 76 >4 III 9:00 
26 DLB4 Male 71 >4 - 5:03 
27 DLB5 Female  87 >4 II 11:00 
28 DLB6 Male 83 >4 II 6:45 
29 DLB7 Male 80 >4 III 4:03 
30 DLB8 Female  76 >4 III 9:00 
31 DLB9 Male 73 >4 I 3:03 
32 DLB10 Female  80 >4 II 11:00 
33 DLB11 Female  71 >4 III 4:00 
34 Cont 1 Male 69 – II/A 5:03 
35 Cont 2 Male 68 – I/0 5:03 
36 Cont 3 Female 64 – I/0 9:00 
37 Cont 4 Male 67 – I/0 5:03 
38 Cont 5 Male 74 – II/A 11:00 
39 Cont 6 Male 86 – II/A 6:45 
40 Cont 7 Female 73 – I/0 4:03 
41 Cont 8 Male 70 – I/A 9:00 
42 Cont 9 Male 61 – I/0 3:03 





Table 15: List of samples exhibiting a rapid neurodegeneration, but pathologically 













1 rDLB1 Male 57 <4 DLB  14:00 
2 rDLB2 Male 65 <4 DLB + PSP some features 16:00 
3 rDLB3 Male 69 <4 DLB+ AGD +PSP + Tauopathy 18:00 
4 rDLB4 Male 71 <4 DLB Neocortical 5:00 
5 rDLB5 Female 75 <4 DLB neocortical + ADIII 13:30 
6 rDLB6 Male 76 <4 DLB neocortical + AD VIC 6:30 
7 DFTL1 Female 73 <4 
DFTL + Motor Neuron Disease + TDP-
43  
5:00 
8 DFTL2 Female 85 <4 AD V + DLFT + TDP-43 +MND 9:00 
9 DFTL3 Female 86 <4 
DFTL + TDP-43 + Motor Neuron Dis-
ease 
3:00 
10 SVD1 Female 81 <4 SVD + AD III B 6:00 
11 SVD2 Female 85 <4 SVD + AD IV + Hippocampal Sclerosis  6:00 
12 SVD3 Male  78 <4 SVD + AD V (INCIP) B/C  3:30 
Table 16: Patient details of Creutzfeldt-Jakob disease cohort. 









1 sCJD (MM1)1 Male 65 <1 MM/MV1 9:45 
2 sCJD (MM1)2 Female 74 <1 MM/MV1 7:50 
3 sCJD (MM1)3 Male 61 <1 MM/MV1 7:00 
4 sCJD (MM1)4 Female 66 <1 MM/MV1 5:05 
5 sCJD (MM1)5 Female 74 <1 MM/MV1 11:00 
6 sCJD (MM1)6 Male 74 <1 MM/MV1 4:50 
7 sCJD (MM1)7 Male 75 <1 MM1 9:00 
8 sCJD (MM1)8 Female 66 <1 MM1 7:00 
9 sCJD (MM2)1 Male 62 <1 MM/MV1+2 11:30 
10 sCJD (MM2)2 Female 84 <1 MM/MV2C 12:00 
11 sCJD (MM2)3 Male 67 <1 MM2 C 9:00 
12 sCJD (MM2)4 Female 58 <1 MV2 10:30 
13 sCJD (MM2)5 Male 50 <1 CJD (NO SUBTYPING) 6:00 
14 sCJD (VV2)1 Male 56 <1 VV2 7:30 
15 sCJD (VV2)2 Male 66 <1 VV2 15:30 
16 sCJD (VV2)3 Female 70 <1 VV2 11:00 
17 sCJD (VV2)4 Female 72 <1 VV2 6:00 





6.1 Interacting partners of high-density prion (HDP) oligomers 
Table 17: Subtype-specific interactors of HDPs from density variable fraction pools 
of controls, rpAD, spAD and sCJD variants. 
 High Density Fractions 
 F12 F13 F14 F15 F16 F17 
Con 
CATD PKP1  CTNB1  PCLO 
SHRM3 CTNB1    CTNB1 
 SHRM3    PGBM 
 LAMP1    CO4A2 






TPIS ACON ZGPAT IDHP  ACON TITIN 
ACON PKP1 ACON   TPIS 
PCLO CTNB1 CTNB1   MYPC3 
PIGR CALL5 PKP1   PFKAP 
FKAP GGCT TITIN   MPCP 
LCN1 IDHP IDHP   ACON 
DMBT1 LCN1 TPIS   GTR1 
MPCP DMBT1 GGCT   MYH10 
GTR1 MPCP GTR1   ENOB 
MUC5A CYTM PCLO   IDHP 
ELNE MYH16 CATD   ALDOC 
SG1D1  MDHM   PCLO 
TRFE  CALL5   ENPL 
MUC5B  PFKAP   MDHC 
CAP7  G6PI   MYL3 
SG2A1  MPCP   ANXA6 
PERM     MYL4 
     ATP6 
     VINC 





KCC2B DIRA2  DIRA2 PKP1 1433S 
KCC2D PKP1   GA2L2  





FRIH SLPI EPDR1 PPT1 SYN1 SYN1 
ASAH1 LCN1 PPT1 CATD SYN2 SYN2 
CATD TPP1 TPP1 EPDR1 CALL5 PACN1 
TPP1 PPT1 FRIH  COF1 COF1 
CO1A2 FRIH CATD  EPDR1 STMN1 
SYN1 DMBT1 ASAH1  CATD CRYM 
PKP1 EPDR1   LCN1 NSF 
A4 KCC2B   COF2 COF2 
 KCC2G   PPT1 TPIS 




F12 F13 F14 F15 F16 F17 
 PKP1    A4 
 ASAH1    ENPL 
 DHX15    PROF2 
     NFL 
     CBR1 
     KCC2B 
     KCC2D 
     KCC2G 
     GRP75 
     TPPP 
     TCPQ 
     MDHM 
     1433E 




1433E PKP1 PIGR PPT1 SYN1 SYN1 
COF1 EPDR1 BPIB1 CATD SYN2 NSF 
ENPL TPP1 SYN1 EPDR1 NSF SYN2 
MDHC CALL5 SYN2  PACN1 PACN1 
CH10 CATD EPDR1  CRYM CRYM 
IDHP ACON PPT1  KCC2B KCC2B 
MYL3 PPT1 CATD  KCC2G KCC2D 
PROF1 SYN1 TPP1  COF1 KCC2G 
SERPH FRIH GGCT  COF2 COF1 
COF2 CTNB1 SYPL1  IDH3A TPIS 
DEST KLK7 SLPI  KCC2D TPPP 
ENOB    TPP1 COF2 
PRDX6    SEPT3 COR1A 
EZRI    ACON SEPT3 
MOES    PCLO CISY 
RADI    EPDR1 ACON 
ANXA5    PKP1 UCHL1 
SET    CATD STX1B 
GSTP1    PHF24 IDH3A 
FABPH    SUCB1 PHF24 
HSPB7     MDHM 
ACON     A4 
PFKAP     PRIO 
RAN     NFL 
PDIA3     CNRP1 
KCRM     GRP75 
TPIS     CATD 
IDH3A     LEG1 
FRIH     SCRN1 




F12 F13 F14 F15 F16 F17 
ANXA6     UBA1 
G6PI     AINX 
GDIB     PRDX5 
CALX     GDIR1 
CALR     GBB5 
PGM1     TPP1 
CISY     EFTU 
GRP75     ARF4 
PPT1     RAC1 
CATD     CDC42 
MYL4     RTN1 
AN32A     TBCB 
AATC      
CALU      
KLC1      
PKP1      
TPP1      
CTNB1      
GDIR1      
CALL5      
ALDH2      
LIS1      
UGPA      
ARP2      
CAPZB      
FUMH      
RS3      
PDK1      
RS19      
MYL9      
NP1L4      





ALDOB PPT1 EPDR1 SYN1 SYN1 SYN1 
FRIH  FRIH PRIO SYN2 CRYM 
EPDR1  CATD SYN2 PRIO SYN2 
PPT1  TPP1 PCLO NSF NSF 
CTNB1  SYN1 COF1 CRYM PRIO 
CATD  PPT1 COF2 KCC2B PACN1 
  CTNB1 EPDR1 COF1 COF1 
  WWC3 PPT1 TPIS TPIS 
   PKP1 SCRN1 SCRN1 
   TIF1B COF2 COF2 
    UBA1 ALDOC 




F12 F13 F14 F15 F16 F17 
    SEPT3 NFL 
    KCC2D CBR1 
    KCC2G KCC2B 
    PACN1 UBA1 
    COR1A COR1A 
    AINX AINX 
    CISY STX1B 
    IDH3A SEPT3 
    ACON NFM 
    GRP75 SEPT9 
    NFL CISY 
    STX1B IDH3A 
    SEPT9 PA1B3 
    PA1B3 CNRP1 
    TPPP DEST 
    PRDX5 DIRA2 
    TCPQ GDIA 
    PSD3 AT1B1 
        DHPR   
 







Disease Relevance  
1433E P62258 14-3-3 protein epsilon Novel Parkinson’s disease 




(Llorens et al., 2017), 
Epilepsy (Schindler et 
al., 2006) 
1433S P31947 14-3-3 protein sigma Novel 


















(Spiegel et al., 2012) 






ALDOB P05062 Fructose-bisphosphate aldolase B 
Known (Zafar 
et al., 2011) 
 










Disease Relevance  
AMPL P28838 Cytosol aminopeptidase Novel  
AN32A P39687 
Acidic leucine-rich nuclear phos-
phoprotein 32 family member A 
Novel 
 
ANXA5 P08758 Annexin A5 
Known (Zafar 
et al., 2011) 
Recurrent Pregnancy 
loss, , 3 (Bogdanova 
et al., 2007) 
ANXA6 P08133 Annexin A6 Novel  
ARF4 P18085 ADP-ribosylation factor 4 Novel  
ARP2 P61160 Actin-related protein 2 Novel  
ASAH1 Q13510 Acid ceramidase Novel 
Farber lipogranulo-
matosis (Muramatsu et 
al., 2002), Alzheimer’s 




ATPase subunit beta-1 
Novel 
 
ATP6 P00846 ATP synthase subunit a Novel 
Neuropathy, ataxia, 
and retinitis pigmen-
tosa (Cha et al., 2015)  
ATPO P48047 









CALL5 Q9NZT1 Calmodulin-like protein 5 Novel  
CALR P27797 Calreticulin Novel 
Alzheimer’s disease 
(Lin, Cao, & Gao, 
2014) 
CALU O43852 Calumenin Novel  
CALX P27824 Calnexin 
Known (W. 
Wang et al., 
2010)  
CAP7 P20160 Azurocidin Novel  
CAPZB P47756 




CATD P07339 Cathepsin D Novel  
Creutzfeldt-Jakob-
disease (Kovacs et al., 
2010) 
CBR1 P16152 Carbonyl reductase [NADPH] 1 Novel  
CDC42 P60953 





chi, Kosaki, Niizuma, 
Hata, & Kosaki, 2015) 
CH10 P61604 




CISY O75390 Citrate synthase, mitochondrial Novel  
CNRP1 Q96F85 
CB1 cannabinoid receptor-inter-
acting protein 1 
Novel 
 
CO1A2 P08123 Collagen alpha-2(I) chain Novel 
Ehlers-Danlos syn-
drome 7B (Weil, D’A-
lessio, Ramirez, & 
Eyre, 1990) 
CO4A2 P08572 Collagen alpha-2(IV) chain Novel 











Disease Relevance  
COF1 P23528 Cofilin-1 
Known (Zafar 
et al., 2011) 
Creutzfeldt-Jakob-dis-
ease (Zafar, Younas, 
et al., 2017) 
COF2 Q9Y281 Cofilin-2 Novel  
COPZ1 P61923 Coatomer subunit zeta-1 Novel  
COR1A P31146 Coronin-1A Novel  
CRYM Q14894 Ketimine reductase mu-crystallin Novel 
Autosomal dominant, 
40 deafness (Abe et 
al., 2003) 
CTNB1 P35222 Catenin beta-1 Novel 
Colorectal cancer (Abe 
et al., 2003)  
CYTM Q15828 Cystatin-M Novel 
Parkinsonism and Alz-
heimer’s disease (Ii, 
Ito, Kominami, & 
Hirano, 1993) 
DEST P60981 Destrin Novel  








dependent RNA helicase DHX15 
Novel 
 
DIRA2 Q96HU8 GTP-binding protein Di-Ras2 Novel  
DMBT1 Q9UGM3 
Deleted in malignant brain tumors 
1 protein 
Novel 
Glioma (Takito et al., 
1999) 
EFTU P49411 





ciency 4 (Valente et 
al., 2007)  
ELNE P08246 Neutrophil elastase Novel 
Cyclic haematopoiesis 
(Horwitz, Benson, Per-
son, Aprikyan, & Dale, 
1999) 
ENOB P13929 Beta-enolase Novel 
Glycogen storage dis-
ease 13 (Comi et al., 
2001) 






EZRI P15311 Ezrin Novel  
FRIH P02794 Ferritin heavy chain 
Known (Comi 
et al., 2001) 
Creutzfeldt-Jakob-dis-






G6PI P06744 Glucose-6-phosphate isomerase Novel 
Hemolytic anemia, 
non-spherocytic, due 
to glucose phosphate 
isomerase deficiency 
(Comi et al., 2001) 










Disease Relevance  
GBB5 O14775 
Guanine nucleotide-binding pro-
tein subunit beta-5 
Novel 
Intellectual develop-
mental disorder with 
cardiac arrhythmia 
(Comi et al., 2001) 
GDIA P31150 




disease (Gawinecka et 
al., 2012) 
GDIB P50395 




GDIR1 P52565 Rho GDP-dissociation inhibitor 1 Novel 
Nephrotic syndrome 8 
(NPHS8) 
GGCT O75223 Gamma-glutamylcyclotransferase Novel  
GRP75 P38646 Stress-70 protein, mitochondrial Novel 
Anemia, sideroblastic, 
4 (Schmitz-Abe et al., 
2015) 
GSTP1 P09211 Glutathione S-transferase P Novel  
GTR1 P11166 
Solute carrier family 2, facilitated 
glucose transporter member 1 
Novel 
Creutzfeldt-Jakob-







(Au et al., 2015) 
HSPB7 Q9UBY9 Heat shock protein beta-7 Novel  
IDH3A P50213 
Isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial 
Novel Alzheimer’s disease 
(Bubber et al., 2005) 
IDHP P48735 




(Bubber et al., 2005) 
ITIH2 P19823 






protein kinase type II subunit beta 
Novel 
Alzheimer’s disease 
(Bubber et al., 2005) 
KCC2D Q13557 
Calcium/calmodulin-dependent 




protein kinase type II subunit 
gamma 
Novel 
KCRM P06732 Creatine kinase M-type Novel  
KLC1 Q07866 Kinesin light chain 1 Novel  






LCN1 P31025 Lipocalin-1 Novel  
LEG1 P09382 Galectin-1 Novel  
LEG3 P17931 Galectin-3 
Known (Bub-




drolase IB subunit alpha 
Novel 
Lissencephaly 1 (Bub-
ber et al., 2005) 




















et al., 2011) 
Creutzfeldt-Jakob-
disease (Gawinecka et 
al., 2013) 
MIF P14174 
Macrophage migration inhibitory 
factor 
Novel  
MOES P26038 Moesin Novel  
MPCP Q00325 
Phosphate carrier protein, mito-
chondrial 
Novel  
MUC5A P98088 Mucin-5AC Novel  
MUC5B Q9HC84 Mucin-5B Novel  




and feeding difficulties 
as well as cerebral at-
rophy (Hamdan et al., 
2014) 
MYH16 Q9H6N6 




MYL3 P08590 Myosin light chain 3 Known  
Creutzfeldt-Jakob-
disease (Zafar et al., 
2015) 
MYL4 P12829 Myosin light chain 4 Novel  
MYL9 P24844 





Myosin-binding protein C, cardiac-
type 
Novel  
NDKB P22392 Nucleoside diphosphate kinase B Novel  
NFL P07196 Neurofilament light polypeptide Novel 
Prion diseases (Inga 
Zerr et al., 2018), fa-
milial Alzheimer’s dis-







(Weston et al., 2017) 
NP1L4 Q99733 




NSF P46459 Vesicle-fusing ATPase Novel  
PA1B3 Q15102 
Platelet-activating factor acetylhy-




Protein kinase C and casein ki-




PCLO Q9Y6V0 Protein piccolo Novel  
PDIA3 P30101 Protein disulfide-isomerase A3 Novel 
Prion disease (Weston 
et al., 2017)f 
PDK1 Q15118 
[Pyruvate dehydrogenase (acetyl-




PERM P05164 Myeloperoxidase Novel  
PFKAP Q01813 
ATP-dependent 6-phosphofructo-












Disease Relevance  
PGBM P98160 
Basement membrane-specific 





PGM1 P36871 Phosphoglucomutase-1 Novel  






PKP1 Q13835 Plakophilin-1 Novel  
PPT1 P50897 Palmitoyl-protein thioesterase 1 Novel 
Ceroid lipofuscinosis, 
neuronal, 1 (CLN1) 
PRDX5 P30044 Peroxiredoxin-5, mitochondrial Novel  
PRDX6 P30041 Peroxiredoxin-6 Novel 
Prion disease (Weston 
et al., 2017) 
PRIO P04156 Major prion protein 
Known (Lin-
den et al., 
2008) 
(Glatzel, Stoeck, See-
ger, Lührs, & Aguzzi, 
2005) Prion spongi-
form encephalopathies 
in human and animals 
PROF1 P07737 Profilin-1 Novel 
Amyotrophic lateral 
sclerosis 18 (Wu et al., 
2012) 
PROF2 P35080 Profilin-2 Novel 
Creutzfeldt-Jakob-
disease (Gawinecka et 
al., 2013) 
PSD3 Q9NYI0 









RADI P35241 Radixin Novel  
RAN P62826 GTP-binding nuclear protein Ran Novel  
RET1 P09455 Retinol-binding protein 1 Novel  
RS19 P39019 40S ribosomal protein S19 Novel  
RS3 P23396 40S ribosomal protein S3 Novel  
RSSA P08865 40S ribosomal protein SA Novel  
RTN1 Q16799 Reticulon-1 Novel  
S10A3 P33764 Protein S100-A3 Novel  
SCRN1 Q12765 Secernin-1 Novel  
SEPT3 Q9UH03 Neuronal-specific septin-3 Novel  
SEPT9 Q9UHD8 Septin-9 Novel  
SERPH P50454 Serpin H1 Novel  
SET Q01105 Protein SET Novel  
SG1D1 O95968 




SG2A1 O75556 Mammaglobin-B Novel  
SHRM3 Q8TF72 Protein Shroom3 Novel  










Disease Relevance  
STMN1 P16949 Stathmin Novel  
STX1B P61266 Syntaxin-1B Novel 
Generalized epilepsy 
with febrile seizures 




ing] subunit beta, mitochondrial 
Novel  
SYN1 P17600 Synapsin-1 
Known (Zafar, 
Shafiq, et al., 
2017) 
Epilepsy X-linked, with 
variable learning disa-
bilities and behavior 
disorders (Schubert et 
al., 2014) 
SYN2 Q92777 Synapsin-2 Novel 
Schizophrenia (Schu-
bert et al., 2014) 
SYPL1 Q16563 Synaptophysin-like protein 1 Novel  
TBCB Q99426 Tubulin-folding cofactor B Novel  
TCPQ P50990 T-complex protein 1 subunit theta Novel  
TIF1B Q13263 




TITIN Q8WZ42 Titin Novel  
TPIS P60174 Triosephosphate isomerase Novel  
TPP1 O14773 Tripeptidyl-peptidase 1 Novel 
Ceroid lipofuscinosis, 
neuronal, 2 (Schubert 





bert et al., 
2014)  
TRFE P02787 Serotransferrin Novel  
TRXR1 Q16881 










lase isozyme L1 
Novel 
Parkinson disease 
(Leroy et al., 1998; 
Liu, Fallon, Lashuel, 
Liu, & Lansbury, 
2002), Alzheimer’s dis-







VINC P18206 Vinculin Novel  
VSIG8 Q5VU13 
V-set and immunoglobulin do-
main-containing protein 8 
Novel 
 
WWC3 Q9ULE0 Protein WWC3 Novel  
ZGPAT Q8N5A5 
Zinc finger CCCH-type with G 
patch domain-containing protein 




Certain HDP interactors were commonly present between the spAD-HDFs and sCJD-
HDFs i.e. nine common interactors between CJD-MM1 and spAD HDFs, likewise, 
nineteen common interactors for CJD-MM2 HDPs and seven from that of sCJD-VV2 
were also found in spAD-HDFs. The number of HDP-interactors for the sCJD-subtypes 
was higher compared to that of controls, spAD and rpAD and the degree of intergroup 
overlap between the HDP-interactors from sCJD subtypes was also the highest, pre-
sumably due to pathological similarities among the prion strains (Table 17 and Table 
18). Aldolase C was commonly identified between HDPs of spAD and VV2. Catenin 
beta-1 and aconitase hydratase were commonly present between the spAD, VV2 and 
MM2 HDFs. Four proteins, namely protein piccolo, plakophilin-1, cathepsin D and tri-
osephosphate isomerase were found commonly interacting with HDPs between the 
HDFs of spAD, CJD-MM1, CJD-VV2 and CJD-MM2 (Figure 51).  
 
 
Figure 51: Venn diagram showing the degree of overlap of HDP-interactors from the 
high-density fractions of spAD and CJD-subtypes. IP-F-spAD: HDP interactors in spAD 
HDFs pools from 12-17, IP-F-MM1: HDP interactors in sCJD-MM1 HDFs pools from 12-
17, IP-F-VV2: HDP interactors in sCJD-VV2 HDFs pools from 12-17IP-F-MM2: HDP in-
teractors in sCJD-MM2 HDFs pools from 12-17. 
Three proteins including calmodulin-like protein 5, endoplasmin and malate dehydro-
genase, mitochondrial, were found in the HDFs of spAD, CJD-MM1 and CJD-MM2. 
Three HDP-interactors, antileukoproteinase, amyloid precursor proteins and 14-3-3E 
were found in the HDFs from sCJD-MM1 and sCJD-MM2 subtypes (Figure 51). The 
high density PrP interactors commonly expressed in all sCJD-subtypes are listed be-

































toF14, F16, F17 
sCJD-VV2:F14 



















tein 1  
S  Novel  sCJD-MM1:F13 to 
F16,  
sCJD-MM2:F13 

































F16, F17,  
sCJD-VV2:F14 to F17 
SYN2 Q92777 Synapsin-2  Cj, Sy. Novel Schizophre-
nia (Schu-
















Novel  sCJD-MM1:F17 
sCJD-MM2:F16, F17, 
sCJD-VV2:F15, F17 


















Cy Novel Autosomal 
dominant, 
40 deafness 


























Cy Novel  sCJD-MM1:F17,  
sCJD-MM2:F16, F17,  
sCJD-VV2:F16, F17 
COF2 Q9Y281 Cofilin-2 Nu matrix 
cy, Ck 



















PROF2 P35080 Profilin-2 Cy, Ck. Novel Creutzfeldt-
Jakob-dise-
ase (Gawi-









 Novel Prion dis-
eases (Inga 
































Novel  sCJD-MM1:F17, 
sCJD-MM2:F12, F17  
sCJD-VV2:F16 
















F12 to F17: HDF pool-12 to 17Ce: centrosome, Sy: Synapse, Sr: sarcoplasmic reticulum, 
C: Cytoplasm, Ck: cytoskeleton, Nu: Nucleus, S: Secreted, Cm: Cell membrane, Sl: Sar-
colemma, Ly: Lysosomes, Mc: Mitochondrion, Syo: Synaptosome, Cj: Cell junction, C V: 
cytoplasmic vesicles, Ga: Golgi apparatus, Pm: phagosome membrane, Px: peroxisome, 
Em: Endosome membrane, Cp: Cell projection, Gc: growth cone, Ms: Melanosome, Er: 
Endoplasmic reticulum and La: Lipid-anchor. The localization of proteins and accession 
number are assigned as in the ExPASy protein database and Uniprot data base, respec-
tively. Relevance with AD, prion and PrP ligand were established by Uniprot database 




Likewise, eleven proteins were uniquely identified in two sCJD subtype (i.e. MV and 
VV2)-specific HDFs. Reported PrP interaction, disease involvement and specific oc-
currence in subtype-specific HDFs are enlisted in Table 20. 
Table 20: High density PrP (HDP) interactors commonly detected between the high-
density fractions of sCJD-MM2 and sCJD-VV2 subtypes. 





















2 COR1A P31146 Coronin-1A 
C, Ck, C, 






3 SEPT3 Q9UH03 
Neuronal-spe-
cific septin-3 
C, Ck, Cj, 
Sy  
Novel   
sCJD-
MM2:F16, 17,  
sCJD-
VV2:F16, F17 




Mc Novel   
sCJD-
MM2:F12. 17,  
sCJD-
VV2:F16, 17 
5 STX1B P61266 Syntaxin-1B 




lepsy with febrile 
seizures plus 9 

















(Kuru, CJD, FFI 
and GSS), Alz-
heimer's disease 






























10 AINX Q16352 
Alpha-in-
ternexin 
















F12 to F17: HDF pool-12 to 17. Ce: centrosome, Sy: Synapse, Sr: sarcoplasmic reticulum, 
C: Cytoplasm, Ck: cytoskeleton, Nu: Nucleus, S: Secreted, Cm: Cell membrane, Sl: Sar-
colemma, Ly: Lysosomes, Mc: Mitochondrion, Syo: Synaptosome, Cj: Cell junction, C V: 
cytoplasmic vesicles, Ga: Golgi apparatus, Pm: phagosome membrane, Px: peroxisome, 
Em: Endosome membrane, Cp: Cell projection, Gc: growth cone, Ms: Melanosome, Er: 
Endoplasmic reticulum and La: Lipid-anchor. The localization of proteins and accession 
number are assigned as in ExPASy protein database and Uniprot data base respectively. 
Relevance with AD, prion and PrP ligand were established by Uniprot database search as 
well. 
Certain HDP-interactors were unique to certain subtype-specific high-density fractions 
from each disease subtype cohort. The disease relevance and reported interaction to 
PrP are detailed in Table 21. We could also identify three interactors common to the 
controls and spAD HDFs including cathepsin D (CTSD), catenin beta-1 (CTNNB1) and 
protein piccolo (PCLO). 
Table 21: Subtype-specific interactors for high-density protein conformers, uniquely 

















brane glycoprotein 1 
Cm, Em, 
Ly 












tor heavy chain H2 
S Novel  
PGBM P98160 
Basement membrane-
specific heparan sulfate 
proteoglycan core pro-
tein 
S Novel  
spAD-
F12 
CAP7 P20160 Azurocidin C Novel  
ELNE P08246 Neutrophil elastase    Novel  
MUC5A P98088 Mucin-5AC  S Novel  
MUC5B Q9HC84 Mucin-5B S Novel  
PERM P05164 Myeloperoxidase  Ly Novel  
SG1D1 O95968 
Secretoglobin family 1D 
member 1 
S Novel  
SG2A1 O75556 Mammaglobin-B    Novel  
TRFE P02787 Serotransferrin S Novel   
spAD-F 
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protein MYH16  



















Zinc finger CCCH-type 
with G patch domain-
containing protein 
Nu  Novel   
spAD-F 
17 




tosa (Cha et 
al., 2015) 
ATPO P48047 
ATP synthase subunit O, 
mitochondrial 
Mc  Novel  
MYH10 P35580 
Myosin-10 (Cellular myo-










C, cardiac-type  
  Novel 
Cardiomyopa-
thy, familial hy-
pertrophic 4  
VINC P18206 Vinculin 




thy, dilated 1W  
rpAD-F 
16 
G2L2 Q8NHY3 GAS2-like protein 2 C, Ck Novel   
rpAD-F 
17 













tor ATP-dependent RNA 
helicase DHX15 







C, Nu, Cp Novel 
Au-Kline syn-












ase, cytoplasmic  
C Novel  
ALDH2 P05091 
Aldehyde dehydrogen-
ase, mitochondrial  
Mc matrix. Novel  
AN32A P39687 
Acidic leucine-rich nu-
clear phosphoprotein 32 
family member A 
Nu, C, ER Novel  






ARP2 P61160 Actin-related protein 2 C, Ck, Cp Novel  
CALR P27797 Calreticulin 
ER, C, S, 
Cell sur-
face, Sr  
Novel 
Alzheimer’s 



































C, Ck  Novel  
CH10 P61604 
10 kDa heat shock pro-
tein, mitochondrial  
Mc matrix Novel  
EZRI P15311 Ezrin 














Rab GDP dissociation 
inhibitor beta 




C Novel  
HSPB7 Q9UBY9 






KCRM P06732 Creatine kinase M-type C Novel  
KLC1 Q07866 Kinesin light chain 1 
Cp, Gc, C 





nit alpha  
C, Ck. C, 




1 (Bubber et 
al., 2005) 





ciency 50  
MYL9 P24844 
Myosin regulatory light 
polypeptide 9 
  Novel  
NP1L4 Q99733 
Nucleosome assembly 
protein 1-like 4 











Mc  Novel  
PGM1 P36871 Phosphoglucomutase-1 C Novel  
PRDX6 P30041 Peroxiredoxin-6 C, Ly  Novel 
Prion disease 
(Weston et al., 
2017) 
PROF1 P07737 Profilin-1 C, Ck. Novel 
Amyotrophic 
lateral sclero-


























Nu, C, Ms Novel  
RET1 P09455 Retinol-binding protein 1 C Novel  
RS19 P39019 
40S ribosomal protein 
S19 
Nu  Novel  
RS3 P23396 
40S ribosomal protein 
S3 
C, Nu, 
Mc, C, Ck,  
Novel  
SERPH P50454 Serpin H1 ER Novel  














ily B member 1 












ARF4 P18085 ADP-ribosylation factor 4 Ga, M Novel  
CDC42 P60953 
Cell division control pro-































(Comi et al., 
2001) 






























C, Ck  Novel  
UCHL1 P09936 
Ubiquitin carboxyl-termi-
nal hydrolase isozyme 
L1 
C, ER Novel 
Parkinson dis-
ease (Leroy et 
al., 1998; Y. 























ary factor 1-beta 












anzani et al., 
1993) 
PSD3 Q9NYI0 
PH and SEC7 domain-
containing protein 3 
Cm, Cj, 
Sy 





porting ATPase subunit 
beta-1 
Cm, Sl Novel  
GDIA P31150 
Rab GDP dissociation 
inhibitor alpha (Rab GDI 
alpha)  








  Novel 
Neurofilamen-
topathy (Wes-
ton et al., 
2017) 
F12 to F17: HDF pool-12 to 17, Ce: centrosome, Sy: Synapse, Sr: sarcoplasmic reticulum, 
C: Cytoplasm, Ck: cytoskeleton, Nu: Nucleus, S: Secreted, Cm: Cell membrane, Sl: Sar-
colemma, Ly: Lysosomes, Mc: Mitochondrion, Syo: Synaptosome, Cj: Cell junction, C V: 
cytoplasmic vesicles, Ga: Golgi apparatus, Pm: phagosome membrane, Px: peroxisome, 
Em: Endosome membrane, Cp: Cell projection, Gc: growth cone, Ms: Melanosome, Er: 
Endoplasmic reticulum and La: Lipid-anchor. The localization of proteins and accession 
number are assigned as in the ExPASy protein database and Uniprot data base, respec-
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µl  Micro liter 
µm  Micro meter 
ACN  Acetonitrile 
AD  Alzheimer’s disease  
ADAM   A Disintegrin- And Metalloproteinase 
AgNO3   Silver nitrate 
AKT / PKB  Protein kinase B  
APOE   Apolipoprotein E  
APP  Amyloid Precursor Protein  
Aβ  amyloid-β  
BACE1  beta-site APP cleaving enzyme 1 
BSA   Bovine serum albumin  
CA1   CA1 region of Hippocampus 
CaMKII  Calcium/calmodulin-dependent protein kinase type II  
cAMP   Cyclic adenosine monophosphate 
CD2AP  CD2 Associated Protein 
CERAD   Consortium to Establish a Registry for Alzheimer's Disease 
Co-IP   Co-immunoprecipitation 
CSF  Cerebrospinal fluid  
ddH2O  Double distilled water 
DFTL  Dementia with fronto-temporal lobar degeneration 
DIA  Data independent acquisition 
DLB  Dementia with Lewy bodies  
DSG2  Desmoglein 2 
DTT   Dithiothreitol  
EDTA  Ethylenediaminetetraacetic acid 
eFAD  Early onset familial AD 
EOAD  Early onset AD 
ERK  Extracellular signal–regulated kinases 
Erk   Extracellular signal–regulated kinases  
ESI  Electrospray Ionization 
FAD  Familial AD 
G-CSF  Granulocyte-colony stimulating factor 
GPI  Glycophosphatidyl Inositol 
GSK3  Glycogen synthase kinase 3-β  
HDFs  High Density Fractions 
HDP  High density prions 
HMW  High molecular weight 
IAA   Iodoacetamide 
IgG  Immunoglobulin G 
IL-13  Interleukin 13 
IL-6  Interleukin 6 
JNK  C-Jun N-terminal kinases 




kD  Kilodalton 
LMW  Low molecular weight 
LOAD  Late onset AD 
LTP  Long-term potentiation  
MAPKs   Mitogen-activated protein kinases  
MCI   Mild Cognitive Impairment 
MCP-1   
MMSE  Mini-Mental State Examination 
MS/MS  Mass spectrometry 
MYLK  Myosin light chain kinase 
Na2S2O3   Sodium thiosulfate 
NaCl  Sodium chloride 
NFkB  
Nuclear factor kappa-light-chain-enhancer of activated B 
cells  
NFTs  Neurofibrillary tangles  
NH4HCO3  Sodium bicarbonate 
NP-40  Nonidet P-40 
NrCAM   neuronal cell adhesion molecule 
oC  Degree Celsius 
p38  Mitogen-activated protein kinases p38 
PBS   Phosphate-buffer saline 
PCA  Principle Component Analysis 
PDM  Product difference of means 
PKA  Protein kinase A 
PKC   Protein kinase C 
PLD3  Phospholipase D3, 
PRNP  Prion protein coding gene 
PrP  Prion protein 
PrPC  Physiological form of Prion Protein  
PrPSc  Scrapie form of Prion Protein 
PSEN1  Presenilin 1 
PSEN2  Presenilin 2 
p-Tau  Phosphorylated Tau 
Q-TOF  Quadrupole-time-of-flight 
rDLB  Rapidly progressive dementia with Lewy bodies 
recPrP  Recombinant PrP 
RFU  Relative fluorescence units 
rP  Pearson's linear correlation coefficient  
rpAD  Rapidly progressive Alzheimer’s disease  
SAPK   stress-activated phospho-kinases 
sAPPα  Shed-APP 
sCJD  Sporadic Creutzfeldt-Jakob disease 
SDS   Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate- Polyacrylamide gel electrophoresis 
spAD  Sporadic Alzheimer’s disease  
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Sequential window acquisition of all theoretical mass spec-
tra- Mass spectrometry  
t1/2  Half life 
Tau  Tubulin associated unit 
TBS   Tris Buffer saline 
TBST  TBS with 0.1% Tween 
TEMED  Tetramethylethylenediamine 
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tM  Threshold Mander's coefficient 
TNF  Tumor necrosis factor 
TREM2  Triggering receptor expressed on myeloid cells 2 
Tris  Tris(hydroxymethyl)aminomethane 
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